<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for apathy in Alzheimer's disease - Ruthirakuhan, MT - 2018 | Cochrane Library</title> <meta content="Pharmacological interventions for apathy in Alzheimer's disease - Ruthirakuhan, MT - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012197.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for apathy in Alzheimer's disease - Ruthirakuhan, MT - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012197.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012197.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for apathy in Alzheimer's disease" name="citation_title"/> <meta content="Myuri T Ruthirakuhan" name="citation_author"/> <meta content="rutmyuri@sri.utoronto.ca" name="citation_author_email"/> <meta content="Nathan Herrmann" name="citation_author"/> <meta content="Eleenor H Abraham" name="citation_author"/> <meta content="Sunnybrook Research Institute" name="citation_author_institution"/> <meta content="Sarah Chan" name="citation_author"/> <meta content="Sunnybrook Health Sciences Centre" name="citation_author_institution"/> <meta content="Krista L Lanctôt" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012197.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/05/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012197.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012197.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012197.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alanine [analogs &amp; derivatives, therapeutic use]; Alzheimer Disease [complications, *psychology]; Antidepressive Agents [therapeutic use]; Apathy [*drug effects]; Azepines [therapeutic use]; Benzhydryl Compounds [therapeutic use]; Biphenyl Compounds [therapeutic use]; Central Nervous System Stimulants [adverse effects, *therapeutic use]; Cholinesterase Inhibitors [therapeutic use]; Methylphenidate [adverse effects, therapeutic use]; Modafinil; Randomized Controlled Trials as Topic; Sulfonamides [therapeutic use]; Valproic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012197.pub2&amp;doi=10.1002/14651858.CD012197.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012197\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012197\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012197.pub2",title:"Pharmacological interventions for apathy in Alzheimer\u0027s disease",firstPublishedDate:"May 4, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012197.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012197.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012197.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012197.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012197.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012197.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012197.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012197.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012197.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012197.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7379 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012197.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0142"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-sec-0136"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/appendices#CD012197-sec-0147"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/table_n/CD012197StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/table_n/CD012197StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for apathy in Alzheimer's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#CD012197-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Myuri T Ruthirakuhan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#CD012197-cr-0003">Nathan Herrmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#CD012197-cr-0004">Eleenor H Abraham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#CD012197-cr-0005">Sarah Chan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information#CD012197-cr-0006">Krista L Lanctôt</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information/en#CD012197-sec-0156">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 May 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012197.pub2">https://doi.org/10.1002/14651858.CD012197.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012197-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012197-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012197-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012197-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012197-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012197-abs-0001" lang="en"> <section id="CD012197-sec-0001"> <h3 class="title" id="CD012197-sec-0001">Background</h3> <p>Despite the high prevalence of apathy in Alzheimer’s disease (AD), and its harmful effects, there are currently no therapies proven to treat this symptom. Recently, a number of pharmacological therapies have been investigated as potential treatments for apathy in AD. </p> </section> <section id="CD012197-sec-0002"> <h3 class="title" id="CD012197-sec-0002">Objectives</h3> <p>Objective 1: To assess the safety and efficacy of pharmacotherapies for the treatment of apathy in Alzheimer's disease (AD).<br/> <br/> Objective 2: To assess the effect on apathy of pharmacotherapies investigated for other primary outcomes in the treatment of AD. </p> </section> <section id="CD012197-sec-0003"> <h3 class="title" id="CD012197-sec-0003">Search methods</h3> <p>We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), MEDLINE, Embase, CINAHL, PsycINFO, LILACS, ClinicalTrials.gov and the World Health Organization (WHO) portal, ICTRP on 17 May 2017. </p> </section> <section id="CD012197-sec-0004"> <h3 class="title" id="CD012197-sec-0004">Selection criteria</h3> <p>Eligible studies were double‐blind, randomized, placebo‐controlled trials (RCTs) investigating apathy as a primary or secondary outcome in people with AD. </p> </section> <section id="CD012197-sec-0005"> <h3 class="title" id="CD012197-sec-0005">Data collection and analysis</h3> <p>Three review authors extracted data. We assessed the risks of bias of included studies using Cochrane methods, and the overall quality of evidence for each outcome using GRADE methods. We calculated mean difference (MD), standardized mean difference (SMD) or risk ratio (RR) with 95% confidence intervals on an intention‐to‐treat basis for all relevant outcome measures. </p> </section> <section id="CD012197-sec-0006"> <h3 class="title" id="CD012197-sec-0006">Main results</h3> <p>We included 21 studies involving a total of 6384 participants in the quantitative analyses. Risk of bias is very low to moderate. All studies reported appropriate methods of randomization and blinding. Most studies reported appropriate methods of allocation concealment. Four studies, three with methylphenidate and one with modafinil, had a primary aim of improving apathy. In these studies, all participants had clinically significant apathy at baseline. Methylphenidate may improve apathy compared to placebo. This finding was present when apathy was assessed using the apathy evaluation scale (AES), which was used by all three studies investigating methylphenidate: MD ‐4.99, 95% CI ‐9.55 to ‐0.43, n = 145, 3 studies, low quality of evidence, but not when assessed with the neuropsychiatric inventory (NPI)‐apathy subscale, which was used by two of the three studies investigating methylphenidate: MD ‐0.08, 95% CI ‐3.85 to 3.69, n = 85, 2 studies, low quality of evidence. As well as having potential benefits for apathy, methylphenidate probably also slightly improves cognition (MD 1.98, 95% CI 1.06 to 2.91, n = 145, 3 studies, moderate quality of evidence), and probably improves instrumental activities of daily living (MD 2.30, 95% CI 0.74 to 3.86, P = 0.004, n = 60, 1 study, moderate quality of evidence), compared to placebo. There may be no difference between methylphenidate and placebo in the risk of developing an adverse event: RR 1.28, 95% CI 0.67 to 2.42, n = 145, 3 studies, low quality of evidence. There was insufficient evidence from one very small study of modafinil to determine the effect of modafinil on apathy assessed with the FrSBe‐apathy subscale: MD 0.27, 95% CI ‐3.51 to 4.05, n = 22, 1 study, low quality of evidence. In all other included studies, apathy was a secondary outcome and participants were not selected on the basis of clinically significant apathy at baseline. We considered the evidence on apathy from these studies to be indirect and associated with publication bias. There was low or very low quality of evidence on cholinesterase inhibitors (ChEIs) (six studies), ChEI discontinuation (one study), antipsychotics (two studies), antipsychotic discontinuation (one study), antidepressants (two studies), mibampator (one study), valproate (three studies) and semagacestat (one study). </p> </section> <section id="CD012197-sec-0007"> <h3 class="title" id="CD012197-sec-0007">Authors' conclusions</h3> <p>Methylphenidate may demonstrate a benefit for apathy and may have slight benefits for cognition and functional performance in people with AD, but this finding is associated with low‐quality evidence. Our meta‐analysis is limited by the small number of studies within each drug class, risk of bias, publication bias, imprecision and inconsistency between studies. Additional studies should be encouraged targeting people with AD with clinically significant apathy which investigate apathy as a primary outcome measure, and which have a longer duration and a larger sample size. This could increase the quality of evidence for methylphenidate, and may confirm whether or not it is an effective pharmacotherapy for apathy in AD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012197-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012197-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012197-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012197-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012197-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012197-abs-0009">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012197-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012197-abs-0006" lang="en"> <h3>Drug treatments for apathy in Alzheimer's disease</h3> <p><b>Review question</b> </p> <p>We wanted to know whether there are any medications that are safe and effective for reducing apathy in people with Alzheimer's disease. </p> <p><b>Background</b> </p> <p>Apathy is a state of reduced interest, lack of initiative and reduced activity. It is a very common symptom of Alzheimer's disease. It is often persistent and it is known to be linked to a lower quality of life, faster decline and more burden on caregivers. Effective treatments of apathy could improve the quality of life for people with Alzheimer's disease and their families. </p> <p><b>What we did</b> </p> <p>We searched for randomized controlled trials (RCTs) up to May 2017 which had compared any medicine with a placebo (dummy pill) and measured the effect on apathy in people with Alzheimer's disease. We were only interested in trials in which it was decided randomly whether the people taking part got the drug of interest or the placebo; this was to make sure that the comparison was as fair as possible. </p> <p><b>What we found</b> </p> <p>We found 21 RCTs involving more than 6300 people with Alzheimer’s disease. Four trials of two different medicines (methylphenidate and modafinil) had been done specifically to study apathy, so all the people taking part were known to be significantly apathetic before the trial started. The other 17 trials had other primary aims, but reported some data on apathy. The trials were generally well designed and conducted. From the three trials with methylphenidate, we found that it may improve apathy, although this depended on how the apathy was measured. The people taking methylphenidate also did slightly better than those taking placebo on scales measuring cognition (thinking, remembering, etc.) and some daily activities, but it was not clear that these effects were big enough to be important in practice. We found no evidence that it caused more side effects than placebo. The quality of this evidence was low or moderate, so we cannot be certain that other similar studies would not have different results. There was only one very small trial with modafinil and there was no evidence that it was effective for apathy. The other 17 trials studied a variety of medicines and included people who were not necessarily significantly apathetic to start with. We therefore thought they were only indirectly relevant to our review question. It is also highly likely that other trials of the same drugs have measured apathy but have not published the results, so we were concerned about possible publication bias (that the studies we found could have been a biased subset). We therefore thought the quality of evidence for all these other medicines was low or very low, meaning that we can have limited or little confidence in the results. </p> <p><b>Conclusions</b> </p> <p>Current evidence suggests that methylphenidate may be useful for treating apathy in Alzheimer's disease. However, more trials should be done specifically targeting apathy in order to improve the overall quality of the evidence. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012197-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-sec-0142">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-sec-0204">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012197-sec-0142"></div> <h3 class="title" id="CD012197-sec-0143">Implications for practice</h3> <section id="CD012197-sec-0143"> <p>Apathy is one of the most prevalent NPS of AD, affecting approximately 20% to 70% of sufferers. It is also associated with a number of negative implications such as increased mortality, increased cognitive and functional deterioration, and increased caregiver burden. However, there are few data available to guide clinicians in treating apathy in AD. Our meta‐analysis is limited by the small number of studies within each drug class, risk of bias, publication bias, imprecision, indirectness of studies included in Objective 2, and inconsistencies between studies. The evidence suggests that methylphenidate may demonstrate a benefit on apathy, although there is limited information available on clinically significant improvement on the AES, and there is some uncertainty regarding the clinical meaningfulness associated with this finding. Methylphenidate may also demonstrate a benefit on cognition in people with AD. However, as methylphenidate has been contraindicated in people with agitation, open‐angle glaucoma, treatment with monoamine oxidase inhibitors, hypertension and other cardiovascular conditions, physicians are encouraged to exercise caution when prescribing methylphenidate in people with AD. </p> <p>Our findings with ChEIs suggest it may also have a benefit for apathy, but there were no subgroup differences identified with AD severity, or ChEI type (approved versus not approved). Nevertheless, there may be a signal for a benefit of donepezil on apathy (<a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a>), and when targeting people with moderate AD. There is very low quality of evidence available for antidepressants and mibampator. </p> </section> <h3 class="title" id="CD012197-sec-0144">Implications for research</h3> <section id="CD012197-sec-0144"> <p>Limitations and challenges encountered in trial design should be addressed to enhance the quality of evidence of future research. For example, while apathy is a well‐defined syndrome with cognitive, affective, and behavioral dimensions, there is a need to refine this definition. Measurements of apathy as diagnostic criteria have been well articulated, but have not yet been fully validated as a treatment target (Cummings 2015). Furthermore, although there are no gold‐standard measurements available for the assessment of apathy, future studies should use scales that have high test/re‐test and interrater reliabilities, such as the AES and the NPI‐apathy subscale (<a href="./references#CD012197-bbs2-0079" title="ClarkeDE , KoJY , KuhlEA , VanReekumR , SalvadorR , MarinRS . Are the available apathy measures reliable and valid? A review of the psychometric evidence. Journal of Psychosomatic Research2011;70(1):73‐97. [PUBMED: 21193104] ">Clarke 2011</a>). This may limit the inconsistency of future findings. Future research should also focus on the subdomains of apathy based on neurobiological, neurochemical and neuroimaging endpoints, as this may assist in identifying new targets for pharmacological intervention. Apathy has also been linked to cognitive and functional deterioration in people with AD. Future studies should therefore include cognitive and functional outcome measures to investigate how targeting apathy may have secondary benefits for cognition and function. Finally, additional studies that target people with AD with clinically‐significant apathy, investigate apathy as a primary outcome measure, and which also have a longer duration and larger sample size, are encouraged. Altogether, this would increase the quality of evidence for methylphenidate, as well as ChEIs, antidepressants and mibamapator, and may justify its future use in clinical practice.. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012197-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012197-sec-0036"></div> <div class="table" id="CD012197-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared to placebo for apathy in Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methylphenidate compared to placebo for apathy in Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Apathy in people with mild‐to‐moderate Alzheimer's disease<br/> <b>Setting:</b> Multicenter, USA and Canada<br/> <b>Intervention:</b> methylphenidate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Methylphenidate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy (AES score)<br/> assessed with: AES<br/> Scale from: 0 to 42<br/> follow‐up: range 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy was ‐4.2 to 0.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.99 lower<br/> (9.55 lower to 0.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES: Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy (NPI‐apathy subscale score)<br/> assessed with: NPI‐apathy subscale<br/> Scale from: 0 to 12<br/> follow‐up: 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy ‐2.6 to ‐1.69</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.08 lower<br/> (3.85 lower to 3.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐ to 2‐point change suggested to be clinically significant in people with a clinically significant apathy (<a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> assessed with: Number of participants reporting ≥ 1 adverse event<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.67 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>684 per 1000<br/> (358 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NPS<br/> assessed with: NPI<br/> Scale from: 0 to 144<br/> follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in NPS was ‐2.08</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 higher<br/> (7.89 lower to 8.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point change suggested to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognition<br/> assessed with: MMSE<br/> Scale from: 0 to 30<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in cognition was ‐1.08 to ‐0.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.79 higher<br/> (0.53 higher to 3.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE: 2‐ to 4‐point change suggested to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in functional performance assessed with: ADL scale<br/> Scale from: 0 to 6<br/> follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was 0.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.50 higher<br/> (0.39 lower to 1.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in functional performance assessed with: IADL scale<br/> Scale from: 0 to 8 for women, and 0 to 5 for men, to avoid potential for gender bias<br/> follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was ‐0.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.30 higher<br/> (0.74 higher to 3.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Change in global disease severity<br/> assessed with: ADCS‐CGIC or CGIC<br/> follow‐up: 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.15 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (17 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dropouts<br/> assessed with: Number of participants who dropped out prior to study completion.<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.10<br/> (0.60 to 7.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/> (25 to 303) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AD:</b> Alzheimer's disease; <b>AEs:</b> Adverse Events; <b>MMSE:</b> Mini‐Mental Status Examination; <b>MD:</b> Mean Difference; <b>NPS:</b> Neuropsychiatric Symptom, <b>SMD:</b> Standardized Mean Difference, <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due imprecision (wide 95% confidence interval).<br/> <sup>2</sup>Quality downgraded one level due to inconsistency (substantial heterogeneity was present).<br/> <sup>3</sup>Quality downgraded one level due to imprecision (only one study, with a relatively small sample size).<br/> <sup>4</sup>Quality downgraded two levels due to very serious imprecision (very wide 95% confidence interval). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012197-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Modafinil compared to placebo for apathy in Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Modafinil compared to placebo for apathy in Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Apathy in people with mild‐to‐moderate Alzheimer's disease<br/> <b>Setting:</b> Single site, USA<br/> <b>Intervention:</b> modafinil<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Modafinil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy<br/> assessed with: FrSBe‐apathy subscale (T‐score converted from raw score)<br/> Scale from: 14 to 70 (raw score)<br/> follow‐up: mean 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy was ‐6.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (3.51 lower to 4.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes on the FrSBe apathy score</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse Events ‐ reported, but not analyzed in this review</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NPS ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognition ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in functional performance<br/> assessed with: ADLQ<br/> Scale from: 0 to 84<br/> follow‐up: mean 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 lower<br/> (1.40 lower to 0.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in global disease severity ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts ‐ reported, but not analyzed in this review</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded two levels due to small sample size and imprecision (wide 95% confidence interval). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012197-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-sec-0164">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012197-sec-0037"></div> <section id="CD012197-sec-0038"> <h3 class="title" id="CD012197-sec-0038">Description of the condition</h3> <p>Current evidence suggests that Alzheimer’s disease (AD), a debilitating neurodegenerative disease, is increasing in prevalence amongst the ageing population. The World Alzheimer Report estimates that by 2015 47 million people worldwide would be living with dementia due to AD, and that this will double every 20 years, to 74.7 million people in 2030 and 131 million people in 2050 (<a href="./references#CD012197-bbs2-0167" title="PrinceM , WimoA , GuerchetM , AliG , WuY , PrinaM . World Alzheimer Report 2015: The Global Impact of Dementia. www.worldalzreport2015.org/downloads/world‐alzheimer‐report‐2015.pdf (accessed 05 February 2016). ">World Alzheimer Report 2015</a>). AD pathology often occurs together with vascular pathology (mixed AD) (<a href="./references#CD012197-bbs2-0150" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>; <a href="./references#CD012197-bbs2-0068" title="AttemsJ , JellingerKA . The overlap between vascular disease and Alzheimer's disease‐‐lessons from pathology. BioMed Central Medicine2014;12:206. ">Attems 2014</a>). AD and mixed AD share cognitive and behavioral symptoms (<a href="./references#CD012197-bbs2-0114" title="KapasiA , SchneiderJA . Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons. Biochimica et Biophysica Acta2016;1862(5):878‐86. ">Kapasi 2016</a>). For the purposes of this systematic review, we will therefore use ‘AD’ when we refer to individuals diagnosed with AD or mixed AD. </p> <p>Neuronal damage and death in the brain of a person with dementia lead to progressive changes in cognition, function and behavior, which negatively impact his or her ability to perform everyday activities of daily living and increase dependence on others. Treating AD is a healthcare and societal priority as the cost of care and the burden on caregivers increases. The governments of countries such as the UK, the USA, Canada, Norway, France and South Korea have developed and implemented national strategic plans to address the changes society will incur as AD prevalence increases (<a href="./references#CD012197-bbs2-0142" title="PrinceM , BryceR , AlbaneseE , WimoA , RibeiroW , FerriCP . The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer's &amp; Dementia2013;9(1):63‐75.e2. ">Prince 2013</a>). </p> <p>Treatment of the symptoms associated with AD is an important aspect of improving the quality of life of people living with AD and their caregivers. One such symptom is apathy which, according to diagnostic criteria outlined by <a href="./references#CD012197-bbs2-0144" title="RobertP , OnyikeCU , LeentjensAF , DujardinK , AaltenP , StarksteinS , et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. European Psychiatry2009;24(2):98‐104. ">Robert 2009</a>, is defined as a disorder of motivation which includes reduced goal‐directed behavior, goal‐directed cognitive activity and emotions, as well as identifiable functional impairments. Apathy is associated with greater caregiver burden, as individuals diagnosed with apathy require more support to initiate and complete activities even when they may still be capable of doing so themselves. The presence of apathy increases with increasing disease severity, and is associated with increased cognitive and functional deficits (<a href="./references#CD012197-bbs2-0158" title="TagarielloP , GirardiP , AmoreM . Depression and apathy in dementia: same syndrome or different constructs? A critical review. Archives of Gerontology and Geriatrics2009;49(2):246‐9. ">Tagariello 2009</a>; <a href="./references#CD012197-bbs2-0112" title="KalesHC , GitlinLN , LyketsosCG . Assessment and management of behavioral and psychological symptoms of dementia. The British Medical Journal2015;350:h369. ">Kales 2015</a>). As such, apathy has been an emerging target of interest for pharmacological interventions. </p> <p>Apathy and depression share some clinical features, such as diminished interest, psychomotor retardation, fatigue/hypersomnia and lack of insight, although depression is characterized by symptoms of dysphoria, suicidal ideation, self‐criticism, guilty feelings, pessimism and hopelessness which are absent in apathy (<a href="./references#CD012197-bbs2-0130" title="MarinRS , FirinciogullariS , BiedrzyckiRC . Group differences in the relationship between apathy and depression. Journal of Nervous and Mental Disease1994;182(4):235‐9. ">Marin 1994</a>). There has been interstudy variability in estimates of the prevalence of apathy in individuals diagnosed with dementia (<a href="./references#CD012197-bbs2-0122" title="LandesAM , SperrySD , StraussME , GeldmacherDS . Apathy in Alzheimer’s disease. Journal of the American Geriatrics Society2001;49(12):1700–7. ">Landes 2001</a>). This variability may be due in part to the inclusion of apathy symptoms on assessment tools of depression, such as the Hamilton Rating Scale of Depression (HAM‐D). However, in a study that administered the Neuropsychiatric Inventory (NPI), a behavioral scale which contains a depression subscale (with no apathy‐related items), and an apathy subscale (with no depression‐related items), there was no correlation between apathy and depression in dementia (<a href="./references#CD012197-bbs2-0125" title="LevyML , CummingsJL , FairbanksLA , MastermanD , MillerBL , CraigAH , et al. Apathy is not depression. Journal of Neuropsychiatry and Clinical Neurosciences1998;10(3):314‐9. ">Levy 1998</a>). Several neuroimaging studies support the biological and phenomenological independence of apathy and depression. These studies report that structural relationships with apathy symptoms are functionally and anatomically distinct from structural relationships with depression (<a href="./references#CD012197-bbs2-0155" title="StarksteinSE , MizrahiR , CapizzanoAA , AcionL , BrockmanS , PowerBD . Neuroimaging correlates of apathy and depression in Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences2009;21(3):259‐65. ">Starkstein 2009</a>; <a href="./references#CD012197-bbs2-0113" title="KangJY , LeeJS , KangH , LeeHW , KimYK , JeonHJ , et al. Regional cerebral blood flow abnormalities associated with apathy and depression in Alzheimer's disease. Alzheimer Disease and Associated Disorders2012;26(3):217‐24. ">Kang 2012</a>). </p> </section> <section id="CD012197-sec-0039"> <h3 class="title" id="CD012197-sec-0039">Description of the intervention</h3> <p>Treatments for apathy include both behavioral and pharmacological interventions, which target psychosocial changes and neurochemical and neuropathological changes in AD, respectively (<a href="./references#CD012197-bbs2-0122" title="LandesAM , SperrySD , StraussME , GeldmacherDS . Apathy in Alzheimer’s disease. Journal of the American Geriatrics Society2001;49(12):1700–7. ">Landes 2001</a>; <a href="./references#CD012197-bbs2-0101" title="GitlinLN , KalesHC , LyketsosCG . Nonpharmacologic management of behavioral symptoms in dementia. The Journal of the American Medical Association2012;308(19):2020‐9. ">Gitlin 2012</a>). </p> <p>Compared to those without significant apathy, the brains of apathetic individuals with AD show some increased pathological changes, such as increased neuronal loss (<a href="./references#CD012197-bbs2-0096" title="FörstlH , BurnsA , LevyR , CairnsN , LuthertP , LantosP . Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease. British Journal of Psychiatry1993;163:364‐8. ">Förstl 1993</a>), neurofibrillary tangles (<a href="./references#CD012197-bbs2-0160" title="TekinS , MegaMS , MastermanDM , ChowT , GarakianJ , VintersHV , et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Annals of Neurology2001;49(3):355‐61. ">Tekin 2001</a>) and white matter hyperintensities (<a href="./references#CD012197-bbs2-0154" title="StarksteinSE , SabeL , VázquezS , DiLorenzoG , MartínezA , PetraccaG , et al. Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer's disease. Journal of Neurology, Neurosurgery, and Psychiatry1997;63(1):66‐73. ">Starkstein 1997</a>) in the frontal lobes and the associated circuits between frontal and subthalamic structures (<a href="./references#CD012197-bbs2-0122" title="LandesAM , SperrySD , StraussME , GeldmacherDS . Apathy in Alzheimer’s disease. Journal of the American Geriatrics Society2001;49(12):1700–7. ">Landes 2001</a>). The cholinergic (<a href="./references#CD012197-bbs2-0116" title="KauferD , CummingsJL , ChristineD . Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. Journal of Neuropsychiatry and Clinical Neurosciences1998;10(1):55‐63. ">Kaufer 1998a</a>), dopaminergic (DA) (<a href="./references#CD012197-bbs2-0145" title="RoccaforteWH , BurkeWJ . Use of psychostimulants for the elderly. Hospital &amp; Community Psychiatry1990;41(12):1330‐3. ">Roccaforte 1990</a>; <a href="./references#CD012197-bbs2-0086" title="DebetteS , KozlowskiO , SteinlingM , RousseauxM . Levodopa and bromocriptine in hypoxic brain injury. Journal of Neurology2002;249(12):1678‐82. ">Debette 2002</a>; <a href="./references#CD012197-bbs2-0139" title="PadalaPR , BurkeWJ , BhatiaSC . Modafinil therapy for apathy in an elderly patient. Annals of Pharmacotherapy2007;41(2):346‐9. ">Padala 2007</a>), serotonergic (<a href="./references#CD012197-bbs2-0110" title="Hoehn‐SaricR , LipseyJR , McLeodDR . Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology1990;10(5):343‐5. ">Hoehn‐Saric 1990</a>; <a href="./references#CD012197-bbs2-0131" title="MarinRS , FogelBS , HawkinsJ , DuffyJ , KruppB . Apathy: a treatable syndrome. Journal of Neuropsychiatry and Clinical Neurosciences1995;7(1):23‐30. ">Marin 1995</a>; <a href="./references#CD012197-bbs2-0070" title="BarnhartWJ , MakelaEH , LatochaMJ . SSRI‐induced apathy syndrome: a clinical review. Journal of Psychiatric Practice2004;10(3):196‐9. ">Barnhart 2004</a>), gamma‐aminobutyric acid (GABA)‐ergic (<a href="./references#CD012197-bbs2-0120" title="LanctôtKL , HerrmannN , RothenburgL , EryavecG . Behavioral correlates of GABAergic disruption in Alzheimer's disease. International Psychogeriatrics2007;19(1):151‐8. ">Lanctôt 2007a</a>) and noradrenergic neurotransmitter systems have been investigated as potential targets for drug intervention, since each system may potentially be associated with the manifestations of apathy in people with AD. </p> <p>Current pharmacological treatments used in the symptomatic management of apathy in individuals with AD include, but are not limited to, the following: </p> <p> <ol id="CD012197-list-0001"> <li> <p>CNS stimulants.</p> </li> <li> <p>Antidepressants.</p> </li> <li> <p>Atypical antipsychotics.</p> </li> <li> <p>Apomorphine.</p> </li> <li> <p>Amantadine.</p> </li> <li> <p>Cholinesterase inhibitors.</p> </li> <li> <p>DA agonists.</p> </li> </ol> </p> </section> <section id="CD012197-sec-0040"> <h3 class="title" id="CD012197-sec-0040">How the intervention might work</h3> <p>Evidence from pharmacological, post mortem and imaging studies suggests that apathy in individuals with AD may be related to abnormalities of cholinergic, DA, serotoninergic, GABA‐ergic and noradrenergic neurotransmitter systems (<a href="./references#CD012197-bbs2-0119" title="LanctôtKL , HerrmannN , MazzottaP . Role of serotonin in the behavioral and psychological symptoms of dementia. Journal of Neuropsychiatry and Clinical Neurosciences2001;13(1):5‐21. ">Lanctôt 2001</a>; <a href="./references#CD012197-bbs2-0097" title="Garcia‐AllozaM , Gil‐BeaFJ , Diez‐ArizaM , ChenCP , FrancisPT , LasherasB , et al. Cholinergic‐serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia2005;43(3):442‐9. ">Garcia‐Alloza 2005</a>; <a href="./references#CD012197-bbs2-0120" title="LanctôtKL , HerrmannN , RothenburgL , EryavecG . Behavioral correlates of GABAergic disruption in Alzheimer's disease. International Psychogeriatrics2007;19(1):151‐8. ">Lanctôt 2007a</a>; <a href="./references#CD012197-bbs2-0121" title="LanctôtKL , MoosaS , HerrmannN , LeibovitchFS , RothenburgL , CotterA , et al. A SPECT study of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;24(1):65‐72. ">Lanctôt 2007b</a>). </p> <p>The cholinergic hypothesis of AD suggests that the degeneration of cholinergic neurons in the basal forebrain, and the associated disruption to cholinergic neurotransmission in the cerebral cortex, contribute greatly to the cognitive impairment experienced by individuals with AD (<a href="./references#CD012197-bbs2-0071" title="BartusRT , DeanRL3rd , BeerB , LippaAS . The cholinergic hypothesis of geriatric memory dysfunction. Science1982;217(4558):408‐14. ">Bartus 1982</a>). Cholinergic deficiency may also limit the neurotransmission between limbic system afferents and neocortical afferents, and hence contributes to the development of apathy in individuals with dementia due to AD. Treatment with acetylcholinesterase inhibitors, such as metrifonate (<a href="./references#CD012197-bbs2-0117" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. ">Kaufer 1998b</a>; <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a>; <a href="./references#CD012197-bbs2-0081" title="CummingsJL , NadelA , MastermanD , CyrusPA . Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology2001;14(2):101‐8. ">Cummings 2001</a>) and tacrine (<a href="./references#CD012197-bbs2-0116" title="KauferD , CummingsJL , ChristineD . Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. Journal of Neuropsychiatry and Clinical Neurosciences1998;10(1):55‐63. ">Kaufer 1998a</a>), has shown benefits for apathy, and provides evidence for the involvement of a cholinergic deficiency in the manifestation of apathy. However, multiple studies suggest that deficiencies in other neurotransmitter systems are also involved (<a href="./references#CD012197-bbs2-0110" title="Hoehn‐SaricR , LipseyJR , McLeodDR . Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology1990;10(5):343‐5. ">Hoehn‐Saric 1990</a>; <a href="./references#CD012197-bbs2-0106" title="HerrmannN , LanctôtKL , KhanLR . The role of norepinephrine in the behavioral and psychological symptoms of dementia. Journal of Neuropsychiatry and Clinical Neurosciences2004;16(3):261‐76. ">Herrmann 2004a</a>; <a href="./references#CD012197-bbs2-0118" title="LanariA , AmentaF , SilvestrelliG , TomassoniD , ParnettiL . Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mechanisms of Ageing and Development2006;127(2):158‐65. ">Lanari 2006</a>; <a href="./references#CD012197-bbs2-0120" title="LanctôtKL , HerrmannN , RothenburgL , EryavecG . Behavioral correlates of GABAergic disruption in Alzheimer's disease. International Psychogeriatrics2007;19(1):151‐8. ">Lanctôt 2007a</a>; <a href="./references#CD012197-bbs2-0121" title="LanctôtKL , MoosaS , HerrmannN , LeibovitchFS , RothenburgL , CotterA , et al. A SPECT study of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;24(1):65‐72. ">Lanctôt 2007b</a>). </p> <p>Many studies have identified changes to the DA system in individuals with dementia (<a href="./references#CD012197-bbs2-0065" title="AllardP , AlafuzoffI , CarlssonA , ErikssonK , EricsonE , GottfriesCG , et al. Loss of dopamine uptake sites labeled with [3H]GBR‐12935 in Alzheimer's disease. European Neurology1990;30(4):181‐5. ">Allard 1990</a>; <a href="./references#CD012197-bbs2-0157" title="StorgaD , VreckoK , BirkmayerJG , ReibneggerG . Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neuroscience Letters1996;203(1):29‐32. ">Storga 1996</a>; <a href="./references#CD012197-bbs2-0083" title="DavidR , KoulibalyM , BenoitM , GarciaR , CaciH , DarcourtJ , et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clinical Neurology and Neurosurgery2008;110(1):19‐24. ">David 2008</a>). In individuals with AD specifically, there is a reduction in DA neurotransmission between the basal ganglia, anterior cingulate and frontal cortex (<a href="./references#CD012197-bbs2-0121" title="LanctôtKL , MoosaS , HerrmannN , LeibovitchFS , RothenburgL , CotterA , et al. A SPECT study of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;24(1):65‐72. ">Lanctôt 2007b</a>). As these neural circuits comprise the brain reward system, which is highly correlated with apathy in individuals without cognitive impairment, it has been proposed that disruption to DA neurotransmission may contribute to the development and severity of apathy in individuals with dementia (<a href="./references#CD012197-bbs2-0076" title="BressanRA , CrippaJA . The role of dopamine in reward and pleasure behaviour‐‐review of data from preclinical research. Acta Psychiatrica Scandinavica. Supplement2005;427:14‐21. ">Bressan 2005</a>; <a href="./references#CD012197-bbs2-0134" title="Mitchell RA , HerrmannN , LanctôtKL . The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neuroscience &amp; Therapeutics2011;17(5):411‐27. ">Mitchell 2011</a>). </p> <p>The role of the serotonergic system in neuropsychiatric symptoms (NPS) has also been studied. The serotonin hypothesis of NPS postulates that a serotonin deficiency increases the likelihood of developing NPS, particularly depression and aggression (<a href="./references#CD012197-bbs2-0162" title="VartiainenH , TiihonenJ , PutkonenA , KoponenH , VirkkunenM , HakolaP , et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatrica Scandinavica1995;91(5):348‐51. ">Vartiainen 1995</a>; <a href="./references#CD012197-bbs2-0084" title="DeBoerSF , KoolhaasJM . 5‐HT1A and 5‐HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. European Journal of Pharmacology2005;526(1‐3):125‐39. ">De Boer 2005</a>; <a href="./references#CD012197-bbs2-0064" title="AlbertPR , BenkelfatC . The neurobiology of depression‐‐revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences2013;368(1615):20120535. ">Albert 2013</a>). In contrast, since selective serotonergic reuptake inhibitors (SSRIs), commonly used in the treatment of depression, have been linked to increased apathy in clinical trials, increased serotonergic neurotransmission has been implicated in the manifestation of apathy in dementia (<a href="./references#CD012197-bbs2-0110" title="Hoehn‐SaricR , LipseyJR , McLeodDR . Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology1990;10(5):343‐5. ">Hoehn‐Saric 1990</a>; <a href="./references#CD012197-bbs2-0131" title="MarinRS , FogelBS , HawkinsJ , DuffyJ , KruppB . Apathy: a treatable syndrome. Journal of Neuropsychiatry and Clinical Neurosciences1995;7(1):23‐30. ">Marin 1995</a>; <a href="./references#CD012197-bbs2-0070" title="BarnhartWJ , MakelaEH , LatochaMJ . SSRI‐induced apathy syndrome: a clinical review. Journal of Psychiatric Practice2004;10(3):196‐9. ">Barnhart 2004</a>). SSRIs influence the DA system through inhibitory mechanisms that involve 5‐HT2C receptors (<a href="./references#CD012197-bbs2-0165" title="WalshSL , CunninghamKA . Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berlin)1997;130(1):41‐58. ">Walsh 1997</a>), and stimulatory mechanisms that involve 5‐HT1B and 5‐HT3 receptors (<a href="./references#CD012197-bbs2-0085" title="DeDeurwaerdèreP , StinusL , SpampinatoU . Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5‐HT3 receptors. Journal of Neuroscience1998;18(16):6528‐38. ">De Deurwaerdère 1998</a>). It has been hypothesized that pharmacological treatments aimed at balancing the serotonin‐dopamine neurotransmitter systems may reduce apathy in those with dementia (<a href="./references#CD012197-bbs2-0063" title="AbeT , MoritaM , KawaiK , MisawaS , KanaiH , HiroseG , et al. Transmission of a t(13q22q) chromosome observed in three generations with segregation of the translocation D1‐trisomy syndrome. Humangenetik1975;30(3):207‐15. ">Abe 1975</a>; <a href="./references#CD012197-bbs2-0084" title="DeBoerSF , KoolhaasJM . 5‐HT1A and 5‐HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. European Journal of Pharmacology2005;526(1‐3):125‐39. ">De Boer 2005</a>; <a href="./references#CD012197-bbs2-0064" title="AlbertPR , BenkelfatC . The neurobiology of depression‐‐revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences2013;368(1615):20120535. ">Albert 2013</a>). </p> <p>Post mortem and neuroimaging studies indicate that there is a loss of GABA‐ergic and noradrenergic (NA) neurons in individuals with dementia (<a href="./references#CD012197-bbs2-0063" title="AbeT , MoritaM , KawaiK , MisawaS , KanaiH , HiroseG , et al. Transmission of a t(13q22q) chromosome observed in three generations with segregation of the translocation D1‐trisomy syndrome. Humangenetik1975;30(3):207‐15. ">Abe 1975</a>; <a href="./references#CD012197-bbs2-0148" title="RossorMN , GarrettNJ , JohnsonAL , MountjoyCQ , RothM , IversenLL . A post‐mortem study of the cholinergic and GABA systems in senile dementia. Brain1982;105(Pt 2):313‐30. ">Rossor 1982</a>; <a href="./references#CD012197-bbs2-0092" title="EllisonDW , BealMF , MazurekMF , BirdED , MartinJB . A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Annals of Neurology1986;20(5):616‐21. ">Ellison 1986</a>; <a href="./references#CD012197-bbs2-0128" title="LoweSL , FrancisPT , ProcterAW , PalmerAM , DavisonAN , BowenDM . Gamma‐aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease. Brain1988;111(Pt 4):785‐99. ">Lowe 1988</a>). It has been hypothesized that since GABA and NA are co‐transmitters with serotonin, pathological changes to the serotonergic system are accompanied by changes to the GABA‐ergic and noradrenergic systems, and that these may play a role in the manifestation of NPS in dementia (<a href="./references#CD012197-bbs2-0148" title="RossorMN , GarrettNJ , JohnsonAL , MountjoyCQ , RothM , IversenLL . A post‐mortem study of the cholinergic and GABA systems in senile dementia. Brain1982;105(Pt 2):313‐30. ">Rossor 1982</a>). <a href="./references#CD012197-bbs2-0120" title="LanctôtKL , HerrmannN , RothenburgL , EryavecG . Behavioral correlates of GABAergic disruption in Alzheimer's disease. International Psychogeriatrics2007;19(1):151‐8. ">Lanctôt 2007a</a> found that higher plasma GABA concentrations were linked to apathy in AD. Noradrenergic changes have not been specifically linked to this symptom (<a href="./references#CD012197-bbs2-0107" title="HerrmannN , LanctôtK , EryavecG , VanReekumR , KhanLR . Growth hormone response to clonidine predicts aggression in Alzheimer's disease. Psychoneuroendocrinology2004;29(9):1192‐7. ">Herrmann 2004b</a>). </p> </section> <section id="CD012197-sec-0041"> <h3 class="title" id="CD012197-sec-0041">Why it is important to do this review</h3> <p>It has been estimated that 97% of individuals with dementia experience one or more NPS over the course of their cognitive impairment, with apathy having a high prevalence of 71% (<a href="./references#CD012197-bbs2-0156" title="SteinbergM , ShaoH , ZandiP , LyketsosCG , Welsh‐BohmerKA , NortonMC , et al. Point and 5‐year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. International Journal of Geriatric Psychiatry2008;23(2):170‐7. ">Steinberg 2008</a>). As apathy has been associated with reduced quality of life and increased functional impairment, caregiver burden, cost of care and risk of institutionalization, it is an important NPS to treat (<a href="./references#CD012197-bbs2-0075" title="BoylePA , MalloyPF , SallowayS , Cahn‐WeinerDA , CohenR , CummingsJL . Executive dysfunction and apathy predict functional impairment in Alzheimer disease. American Journal of Geriatric Psychiatry2003;11(2):214‐21. ">Boyle 2003</a>; <a href="./references#CD012197-bbs2-0111" title="HurtC , BhattacharyyaS , BurnsA , CamusV , LiperotiR , MarriottA , et al. Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dementia and Geriatric Cognitive Disorders2008;26(2):138‐46. ">Hurt 2008</a>; <a href="./references#CD012197-bbs2-0163" title="Vilalta‐FranchJ , Calvó‐PerxasL , Garre‐OlmoJ , Turró‐GarrigaO , López‐PousaS . Apathy syndrome in Alzheimer's disease epidemiology: prevalence, incidence, persistence, and risk and mortality factors. Journal of Alzheimer's Disease2013;33(2):535‐43. ">Vialta‐Franch 2013</a>) </p> <p>Behavioral interventions, usually involving caregivers, may be a safe treatment option as they are not accompanied by the adverse effects that can be associated with pharmacological interventions. They have a beneficial impact on the frequency and severity of NPS overall, and on caregivers’ negative reactions towards NPS (<a href="./references#CD012197-bbs2-0138" title="OvershottR , ByrneJ , BurnsA . Nonpharmacological and pharmacological interventions for symptoms in Alzheimer's disease. Expert Review of Neurotherapeutics2004;4(5):809‐21. ">Overshott 2004</a>; <a href="./references#CD012197-bbs2-0077" title="BrodatyH , ArasaratnamC . Meta‐analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. American Journal of Psychiatry2012;169(9):946‐53. ">Brodaty 2012</a>). However, caregiver‐delivered behavioral interventions have not been well investigated in apathetic individuals with AD. </p> <p>Currently, there are pharmacological recommendations for the management of cognitive and functional impairments and NPS in individuals with AD (<a href="./references#CD012197-bbs2-0108" title="HerrmannN , LanctôtKL , HoganDB . Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012. Alzheimer's Research &amp; Therapy2013;5(Suppl 1):S5. ">Herrmann 2013</a>). However, there are no formal pharmacological recommendations specifically about the treatment of apathy in AD. There have been a few pharmacological studies in which treating apathy has been the primary objective of the study. There have also been many studies, involving several different classes of drugs, in which the primary outcome measures have been cognition or other non‐cognitive symptoms, but which have reported on apathy as a secondary outcome measure. Claims for efficacy against apathy have been made on the basis of this second class of study (<a href="./references#CD012197-bbs2-0072" title="BermanK , BrodatyH , WithallA , SeeherK . Pharmacologic treatment of apathy in dementia. American Journal of Geriatric Psychiatry2012;20(2):104‐22. [PUBMED: 21841459] ">Berman 2012</a>). As a result, a systematic review is required, which considers the nature and quality of the evidence, to determine the safety, tolerability and efficacy of current pharmacological options for the treatment of apathy and to identify the most promising drugs to target for future investigation. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012197-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-sec-0169">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012197-sec-0042"></div> <p>Objective 1: To assess the safety and efficacy of pharmacotherapies for the treatment of apathy in Alzheimer's disease (AD).<br/> <br/> Objective 2: To assess the effect on apathy of pharmacotherapies investigated for other primary outcomes in the treatment of AD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012197-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-sec-0170">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012197-sec-0043"></div> <section id="CD012197-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012197-sec-0045"> <h4 class="title">Types of studies</h4> <p>We included all placebo‐controlled, parallel and cross‐over randomized controlled trials (RCTs) that investigated medications to treat apathy in AD or mixed AD, or both. Apathy was a primary (Objective 1) or secondary (Objective 2) outcome in the included studies. </p> <p>We also included parallel and cross‐over RCTs that compared two or more medications for treating apathy in people with AD or mixed AD. </p> </section> <section id="CD012197-sec-0046"> <h4 class="title">Types of participants</h4> <p>We included participants who met standardized diagnostic criteria for AD or mixed AD (e.g. the Diagnostic and Statistical Manual of Mental Disorders (IV, IV Text Revision, 5) (<a href="./references#CD012197-bbs2-0067" title="American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th Edition. Arlington, VA: American Psychiatric Association, 2013. ">APA 2013</a>), the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS‐ADRDA) (<a href="./references#CD012197-bbs2-0132" title="McKhannG , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>), the National Institute on Aging/Alzheimer’s Association (NIA/AA) (<a href="./references#CD012197-bbs2-0133" title="McKhannGM , KnopmanDS , ChertkowH , Hyman , BT , JackCRJr , KawasCH , et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer's &amp; Dementia2011;7(3):263‐9. ">McKhann 2011</a>) and the International Classification of Diseases and Related Health Problems 10<sup>th</sup> Revision (ICD‐10) (<a href="./references#CD012197-bbs2-0166" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: clinical descriptions and diagnostic guidelines. 1992. apps.who.int/iris/handle/10665/37958#sthash.Vaxjp53U.dpuf (accessed 05 February 2016). ">WHO 1992</a>)). </p> <p>We extracted information on baseline scores of apathy in order to determine if study populations had clinically significant apathy. However this was not an inclusion criterion for this meta‐analysis. Although some authors reported on clinically significant apathy using the Apathy Evaluation Scale (AES), Frontal Systems Behaviour Scale (FrSBe) Tscore, or clinical judgement, we classified studies as including participants with clinically significant apathy when the mean NPI‐apathy subscore was more than three at baseline (<a href="./references#CD012197-bbs2-0135" title="MulinE , LeoneE , DujardinK , DelliauxM , LeentjensA , NobiliF , et al. Diagnostic criteria for apathy in clinical practice. International Journal of Geriatric Psychiatry2011;26(2):158‐65. [PUBMED: 20690145] ">Mulin 2011</a>). </p> </section> <section id="CD012197-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We included any pharmacological interventions. We applied no restrictions to duration of treatment or to medication dosage. </p> </section> <section id="CD012197-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>For Objective 1 – the assessment of efficacy and safety of drugs being investigated specifically for the treatment of apathy in AD – we included the following outcomes in the review: </p> <section id="CD012197-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012197-list-0002"> <li> <p>Apathy measured by a scale which specifically measures apathy, either exclusively or as one of its components. The scales include, but are not limited to, the Apathy Evaluation Scale (AES), the apathy component of the Clinical Global Impressions of Change scale (CGI‐C apathy), the Neuropsychiatric Inventory (NPI) apathy subscale, the Lille Apathy Rating Scale (LARS), the FrSBe–Apathy component, the Nurses’ Observation Scale for Inpatient Evaluation (NOSIE), the Brief Psychiatric Rating Scale (BPRS) and the Sandoz Clinical Assessment‐Geriatric Scale (SCAG<i>).</i> </p> </li> <li> <p>Adverse effects.</p> </li> </ol> </p> </section> <section id="CD012197-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012197-list-0003"> <li> <p>Neuropsychiatric symptoms other than apathy.</p> </li> <li> <p>Cognition.</p> </li> <li> <p>Functional performance.</p> </li> <li> <p>Changes in global disease severity (CGI‐C).</p> </li> <li> <p>Dropouts due to adverse events (AEs).</p> </li> </ol> </p> <p>For Objective 2, when we considered studies reporting apathy as a secondary outcome measure, we evaluated the effect on apathy only. This was because these studies are likely to form only a small and unrepresentative subset of studies investigating the other outcomes. We considered them a useful source of preliminary information about possible effects on apathy, but an unsuitable dataset to estimate effects on safety or our secondary outcomes. </p> </section> </section> </section> <section id="CD012197-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012197-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>), the Cochrane Dementia and Cognitive Improvement Group Specialized Register, on 15 June 2016 and 05 May 2017. We used the following search terms: apathy, apathetic, BPSD. </p> <p>The Information Specialist maintains ALOIS, which contains dementia and cognitive improvement studies identified from the following sources: </p> <p> <ol id="CD012197-list-0004"> <li> <p>Monthly searches of a number of major healthcare databases: MEDLINE, Embase, CINAHL, PsycINFO and LILACS. </p> </li> <li> <p>Monthly searches of a number of trial registers: the metaRegister of Controlled Trials; the Umin Japan Trial Register; the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (which covers <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a>, ISRCTN, the Chinese Clinical Trials Register, the German Clinical Trials Register, the Iranian Registry of Clinical Trials, the Netherlands National Trials Register and others). </p> </li> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library). </p> </li> <li> <p>Six searches a month of a number of grey literature sources: ISI Web of Knowledge with Conference Proceedings; Index to Theses; and Australasian Digital Theses. </p> </li> </ol> </p> <p>We did not limit the search by language or date of publication. If we found articles in languages other than English, we ensured that these articles were translated and screened for potential inclusion. </p> <p>We performed separate searches of many of the above‐named sources to ensure that we retrieved the most up‐to‐date results. The search strategy that we used for the retrieval of trial reports from MEDLINE is in Appendix 1. </p> </section> <section id="CD012197-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We performed electronic searches only.</p> </section> </section> <section id="CD012197-sec-0054"> <h3 class="title" id="CD012197-sec-0054">Data collection and analysis</h3> <section id="CD012197-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Three review authors independently screened the citations identified from the literature search by title and abstract. We identified potentially relevant articles and obtained the full‐text articles for assessment. Three review authors independently assessed these articles according to the previously‐mentioned criteria. We resolved any disagreements by discussion, and involved a third review author if necessary, until we reached consensus. We contacted the study authors for further information when necessary. We identified duplicate citations through author names, institution name or participant data. </p> <p>For articles which investigated apathy as a primary outcome measure (Objective 1), we contacted the study authors for further information on our primary and secondary outcome measures when necessary. For articles which investigated apathy as a secondary outcome measure (Objective 2), we contacted the study authors for further information about the change in apathy, when necessary. </p> </section> <section id="CD012197-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Three review authors independently extracted the data using a data extraction form. We obtained missing data from the study authors when possible. One review author entered the data into Review Manager 5 (RevMan) (<a href="./references#CD012197-bbs2-0143" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and the other review authors checked for accuracy. We resolved any discrepancies by consensus. </p> </section> <section id="CD012197-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risks of bias in accordance with the Cochrane 'Risk of bias' assessment tool for assessing quality and risk of bias (<a href="./references#CD012197-bbs2-0109" title="HigginsJPT , AltmanDG , Sterne , JAC , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We compared 'Risk of bias' ratings, and resolved discrepancies through discussion with co‐authors. The tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding (participants, raters and personnel), the completeness of outcome data, selective reporting and other potential sources of biases (e.g. carry‐over bias in cross‐over trials, recruitment bias in cluster‐RCTs or bias due to early stopping in specific situations). Where the included study provided inadequate details of randomization and other characteristics of the trials, we contacted the study authors to obtain further information. </p> <p>We assessed the risk of bias in each domain and categorized it into one of the following.</p> <p> <ol id="CD012197-list-0005"> <li> <p>Low risk of bias: plausible bias that is unlikely to seriously alter the results.</p> </li> <li> <p>High risk of bias: plausible bias that seriously weakens confidence in the results.</p> </li> <li> <p>Unclear risk of bias: plausible bias that raises some doubts about the results. </p> </li> </ol> </p> </section> <section id="CD012197-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed the longer ordinal scales in meta‐analyses as continuous data. We converted shorter ordinal scales into dichotomous data by combining adjacent categories into two groups and defining one of the grouped categories as the event. </p> <p>For continuous data, the measure of treatment effect was the mean difference (MD) with the 95% confidence interval (CI) if the pooled trials used the same rating scale or test, or the standardized mean difference (SMD) with a 95% CI if the trials used different scales to measure the same outcome. </p> <p>For dichotomous data, the measure of treatment effect was the relative risk (RR) and its 95% CI. </p> <p>In order to interpret findings, we used the GRADE approach (<a href="./references#CD012197-bbs2-0103" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. The British Medical Journal2008;336(7650):924‐6. ">Guyatt 2008</a>) to assess the overall quality of evidence for all outcomes with pooled data, rating each one as either high, moderate, low or very low quality. The GRADE ratings take into account risk of bias, imprecision, inconsistency, publication bias and indirectness, and express the degree of confidence one can have that the effect estimate is close to the true effect. </p> </section> <section id="CD012197-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>Carry‐over effects are a concern associated with cross‐over trials. If a study reported significant carry‐over effects, we used only data from the first phase of a cross‐over study. If a study reported no carry‐over effects, then we included data (paired data if possible) from both treatment phases. </p> </section> <section id="CD012197-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>In the event of missing information, we requested unreported data from the author(s) of the original study. We preferred intention‐to‐treat (ITT) data when available. In the case of missing data for non‐completers, we recorded any imputation methods used by the study authors and considered the use of sensitivity analyses to assess the impact on the results of different methods of dealing with missing data. </p> </section> <section id="CD012197-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD012197-sec-0062"> <h5 class="title">Clinical heterogeneity</h5> <p>We considered separately studies that were related by drug group. Within each group of studies, we noted the obvious sources of heterogeneity and considered these in the analyses. </p> </section> <section id="CD012197-sec-0063"> <h5 class="title">Statistical heterogeneity</h5> <section id="CD012197-sec-0064"> <h6 class="title">Visual inspection</h6> <p>We inspected graphs to assess the possibility of statistical heterogeneity.</p> </section> <section id="CD012197-sec-0065"> <h6 class="title">Use of the I<sup>2</sup> statistic </h6> <p>We used the I<sup>2</sup> statistic to identify heterogeneity across the included studies. If the I<sup>2</sup> statistic value was greater than 40%, we took this value to represent significant heterogeneity. </p> </section> </section> </section> <section id="CD012197-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We performed a comprehensive search and included trial registries to minimize the risk of reporting bias, which may arise when publication is influenced by the nature and direction of results (<a href="./references#CD012197-bbs2-0091" title="EggerM , Davey‐SmithG , SchneiderM , MinderCSO . Bias in meta‐analysis detected by a simple, graphical test. The British Medical Journal1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> <section id="CD012197-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model for analyses with sufficient homogeneity. If there was significant heterogeneity, we used a random‐effects model. If possible, we conducted analyses in accordance with the principles of ITT. </p> </section> <section id="CD012197-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Data permitting, we conducted subgroup analyses for each drug group to examine the effect of the following: </p> <p> <ol id="CD012197-list-0006"> <li> <p>Treatment duration.</p> </li> <li> <p>Disease severity and diagnostic group (i.e. AD or mixed dementia).</p> </li> </ol> </p> <p>If there were high levels of heterogeneity, we explored the plausible causes of heterogeneity. If we identified statistical heterogeneity, we used the strategies recommended by the <i>Cochrane Handbook for Systematic Reviews of Inteventions</i>, Section 9.5.3 and completed a random‐effects meta‐analysis to incorporate heterogeneity among studies (<a href="./references#CD012197-bbs2-0088" title="DeeksJJ , HigginsJPT , AltmanDG , editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane‐handbook.org2011. ">Deeks 2011</a>). </p> </section> <section id="CD012197-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>In order to address the robustness of our results to potential risks of bias, we repeated the previous analyses, excluding studies at high risk of bias. We identified issues suitable for sensitivity analysis during the review process. </p> <section id="CD012197-sec-0070"> <h5 class="title">Data presentation: 'Summary of findings' tables</h5> <p>We used the GRADE approach to assess the quality of evidence behind each estimate of treatment effect (<a href="./references#CD012197-bbs2-0151" title="SchünemannH , HillS , GuyattG , AklEA , AhmedF . The GRADE approach and Bradford Hill's criteria for causation. Journal of Epidemiology and Community Health2011;65(5):392‐5. ">Schünemann 2011</a>). For each comparison, we presented key findings, including a summary of the amount of data and the magnitude of the effect size. For comparisons in Objective 1, we presented the overall quality of the evidence in a 'Summary of findings' table, created using GRADEpro software (<a href="http://www.gradepro.org" target="_blank">www.gradepro.org</a>). We preselected the following outcomes. </p> <p> <ol id="CD012197-list-0007"> <li> <p>Apathy.</p> </li> <li> <p>Adverse effects.</p> </li> <li> <p>Overall behavioral symptoms.</p> </li> <li> <p>Cognition.</p> </li> <li> <p>Function.</p> </li> <li> <p>Clinical global impression.</p> </li> <li> <p>Dropouts due to AEs.</p> </li> </ol> </p> <p>As described above, apathy was the only outcome measure evaluated for those studies assessing apathy as a secondary outcome measure (Objective 2). We did not produce ‘Summary of findings’ tables for Objective 2 comparisons. However, we described the quality of evidence, using the GRADE approach, along with the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012197-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012197-sec-0071"></div> <section id="CD012197-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD012197-sec-0073"> <h4 class="title">Results of the search</h4> <p>Our search of the database and other electronic sources yielded 5295 references and 675 references, respectively. After de‐duplication and first‐assess removal of non‐relevant references by Anna Noel‐Storr (Information Specialist of the CDCIG), MR and EHA, or MR and SC independently assessed the remaining 1566 references for relevance. Of these, we ruled out 1504 references as they either did not investigate apathy as a primary or secondary outcome measure, did not investigate the efficacy of a pharmacological agent, did not conduct a double‐blind, randomized, placebo‐controlled trial, and/or did not include people with AD. This left 62 full‐text articles for assessment by MR, EHA and SC independently. These articles reported on apathy as a primary outcome measure, or used a scale such as the NPI to evaluate apathy as a secondary outcome measure. We contacted authors when data were not sufficiently reported for extraction for this review. We received further information from <a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> and <a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a>.<br/> <br/> Forty‐one studies which investigated apathy as a secondary outcome measure did not publish or provide upon request sufficient data on apathy; we therefore excluded them from this review. Of the 21 studies included in this meta‐analysis, four investigated apathy as a primary outcome (Objective 1), and 17 studies investigated apathy as a secondary outcome (Objective 2). </p> <p>See <a href="#CD012197-fig-0001">Figure 1</a> for the study flow diagram. </p> <div class="figure" id="CD012197-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="2Study flow diagram." data-id="CD012197-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>2Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012197-sec-0074"> <h4 class="title">Included studies</h4> <p>The characteristics of the 21 included studies in this review are summarized in the <a href="./references#CD012197-sec-0162" title="">Characteristics of included studies</a> table. </p> <p>Twenty‐one studies met our inclusion criteria for this meta‐analysis. We provide further information on study and participant characteristics in <a href="#CD012197-tbl-0003">Table 1</a>. All of the trials included in this meta‐analysis were randomized, double‐blind and placebo‐controlled. All but three studies (<a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a>; <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>) were multicenter trials. All studies included people with possible or probable AD according to standardized criteria (NINCDS‐ADRDA, DSM‐IV‐TR, or ICD‐10). </p> <div class="table" id="CD012197-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>STUDY DURATION</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N OF PARTICIPANTS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN AGE (YRS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN BL NPI‐APATHY (SD) score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COUNTRY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NUMBER OF SITES</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TREATMENT GROUPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>METHYLPHENIDATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks Cross‐over design: 2 treatment phases of 2 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA), and apathy (NPI‐apathy subscale ≥ 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.9 (7.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.9 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (10 mg twice a day)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants<br/> <b>Group 1:</b> 29<br/> <b>Group 2:</b> 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA), and clinically significant apathy for at least 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 7 (2)<br/> <b>Group 2:</b> 7 (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (target: 20 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants<br/> <b>Group 1:</b> 30<br/> <b>Group 2:</b> 30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia of the AD type (DSM‐IV‐TR), and presence of apathy (AES &gt; 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/> <br/> (AES only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (target: 20 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>MODAFINIL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 11<br/> <b>Group 2:</b> 11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA criteria) and clinically significant apathy (FrSBe Tscore ≥ 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 75.3 (8.3)<br/> <b>Group 2:</b> 29.4 (7.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Modafinil (200 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>CHOLINESTERASE INHIBITORS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 103 </p> <p><b>Group 2:</b> 105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD with cerebrovascular disease (but not vascular dementia) (NINCDS‐ADRDA criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 85.4<br/> <b>Group 2:</b><br/> 85.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 14.4 (5.4)<br/> <b>Group 2:</b> 14.4 (5.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil ‐ 5 mg/day for 28 days. 10 mg/day after 28 days based on tolerability.<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 144<br/> <b>Group 2:</b> 146 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD (DSM‐IV and NINCDS‐ADRDA criteria)<br/> <br/> moderate‐severe AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 11.7 (0.35)<br/> <b>Group 2:</b> 12.0 (0.34) ** </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 3.48 (0.29)<br/> <b>Group 2:</b><br/> 3.48<br/> (0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada, Australia, France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil ‐ 5 mg/day for 28 days. 10 mg/day after 28 days based on tolerability.<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 3 ‐ 6 months (12 ‐ 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 1347<br/> <b>Group 2:</b> 686 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 2.34 (3.2)<br/> <b>Group 2:</b><br/> 2.32 (3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada, Great Britain, South Africa, Australia, and New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Galantamine<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 273<br/> <b>Group 2:</b> 135 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Metrifonate (2 weeks – 2.0 mg/kg, followed by 0.65 mg/kg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 273<br/> <b>Group 2:</b> 135 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 73.5 (8.1)<br/> <b>Group 2:</b> 73.7 (7.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 18.8 (5)<br/> <b>Group 2:</b> 19.4 (4.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Metrifonate (2 weeks – 2.0 mg/kg, followed by 0.65 mg/kg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 177<br/> <b>Group 2:</b> 87 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)</p> <p>mild‐moderate AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 74.6 (8.3)<br/> <b>Group 2 :</b> 74.5 (7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 18.7 (4.76)<br/> <b>Group 2:</b> 18.7 (4.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (additional sites are not disclosed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 50 mg, OD<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>CHOLINESTERASE DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 21<br/> <b>Group 2:</b> 19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> moderate‐severe AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 8.1(5.2)<br/> <b>Group 2:</b> 10 (5.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 3.29 (4.0)<br/> <b>Group 2:</b><br/> 2.16 (4.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil,<br/> rivastigmine,<br/> galantamine (oral only)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ATYPICAL ANTIPSYCHOTICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 132<br/> <b>Group 2:</b> 125<br/> <b>Group 3:</b> 134 <br/> <b>Group 4:</b> 129<br/> <b>Group 5:</b> 129 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA criteria and DSM‐IV‐TR), and clinically significant psychotic symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6 (10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 3.2 (3.9)<br/> <b>Group 2:</b> 3.2 (3.7)<br/> <b>Group 3:</b> 3.4 (3.9)<br/> <b>Group 4:</b> 3.4 (3.7)<br/> <b>Group 5:</b> 3.0 (3.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe, Australia, Israel, Lebanon, and South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 7.5 mg OLZ<br/> <b>Group 2:</b> 5 mg OLZ<br/> <b>Group 3:</b> 2.5 mg OLZ <br/> <b>Group 4:</b> 1.0 mg OLZ<br/> <b>Group 5:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 36 weeks (12 weeks of treatment) data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 100<br/> <b>Group 2:</b> 94<br/> <b>Group 3:</b> 85<br/> <b>Group 4:</b> 142 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia of the AD type (DSM‐IV) or probable AD (NINCDS‐ADRDA) and daily delusions, hallucinations, agitation, or aggression over 4 weeks prior to study entry </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.9 (7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 15 (5.4)<br/> <b>Group 2:</b> 14.9 (6.1)<br/> <b>Group 3:</b> 15.7 (6.1)<br/> <b>Group 4:</b> 14.7 (5.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> OLZ<br/> <b>Group 2:</b> QUE<br/> <b>Group 3:</b> RIS<br/> <b>Group 4:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ANTIPSYCHOTIC DISCONTUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 28<br/> <b>Group 2:</b> 27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia diagnosis according to ICD‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.4 (1.5)<b>Group 2:</b> 1.9 (1.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Antipsychotics (haloperidol, risperidone, or olanzapine)<br/> <b>Group 2:</b><br/> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ANTIDEPRESSANTS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks: Cross‐over design: 2 treatment phases of 4 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary degenerative dementia (DSM‐IV) and probable AD (NINCDS‐ADRDA), and significant behavioral problems (NPI ≥ 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.27 (3.5)<br/> <b>Group 2:</b><br/> 1.45 (3.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Sertraline (100 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 94<br/> <b>Group 2:</b> 92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA), and significant behavioral problems (NPI ≥ 8), and clinically significant agitation on the NPI &gt; 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 78 (9)<br/> <b>Group 2:</b> 79 (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 17 (6.2)<br/> <b>Group 2:</b> 14.4 (6.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 6 (0.9)<br/> <b>Group 2:</b><br/> 6 (0.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Citalopram (30 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>MIBAMPATOR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 63<br/> <b>Group 2:</b> 69 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA) (DSM‐IV‐TR), and clinically significant agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 77.2 (8.2)<br/> <b>Group 2:</b> 77.7 (7.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 16.0 (6.1) <b>Group 2:</b> 18 (5.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Mibampator (target dose: 3 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>VALPROATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks: Cross‐over design: 2 treatment phases of 6 weeks with a 2‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 14<br/> <b>Group 2:</b> 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA), primary degenerative dementia (DSM‐IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 2.4 (3.8)<br/> <b>Group 2:</b><br/> 3.0(4.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (mean dose: 1134.6 (400.1) mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks: Cross‐over design: 2 treatment phases of 3 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 42<br/> <b>Group 2:</b> 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senile dementia (NINCDS‐ADRDA)(DSM‐IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.4 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (2 x 240 mg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months (+ 2‐month single‐blind placebo phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 153<br/> <b>Group 2:</b> 160 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 74.9<br/> <b>Group 2:</b> 76.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 16.9 (3.0)<br/> <b>Group 2:</b> 16.9 (2.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.1 (2.7)<br/> <b>Group 2:</b><br/> 1.2 (2.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (flexible‐dose) (mean modal dose: 250 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>SEMAGACESTAT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0016" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease2016;54(1):373‐81. [PUBMED: 27567808] ">Semgacestat trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 463<br/> <b>Group 2:</b> 472<br/> <b>Group 3:</b> 473 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild‐moderate AD (NINCDS‐ADRDA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 72.7 (7.9)<br/> <b>Group 2:</b> 73 (8.5)<br/> <b>Group 3:</b> 73.3 (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 20.9 (3.5)<br/> <b>Group 2:</b> 20.8 (3.5)<br/> <b>Group 3:</b> 20.9 (3.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> LY100<br/> <b>Group 2:</b> LY140<br/> <b>Group 3:</b> Placebo </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: Alzheimer's disease, BL: baseline, DSM: Diagnostic and Statistical Manual of Mental Disoders, FrSBe: Frontal Systems Behavior Scale, ICD: International Classification of Diseases, LY: LY450319 (Eli Lillyand Company study drug), NINCDS‐ADRDA: National Institute of Neurological and Communicative disorders and the Alzheimer's Disease and Related Disorders Association, NPI: Neuropsychiatric Inventory, OLZ: olanzapine, QUE: quetiapine, RIS: risperidone, SD: standard deviation. </p> </div> </div> <section id="CD012197-sec-0075"> <h5 class="title">Objective 1:</h5> <p>Four studies investigated the effect of a pharmacological treatment on apathy as a primary outcome measure. The drugs studied were methylphenidate and modafinil, both compared to placebo. We treat modafinil and methylphenidate separately in this review and meta‐analysis. Although both are CNS stimulants, their mechanisms of action differ. Modafinil activates glutamatergic circuits while inhibiting GABA neurotransmission (<a href="./references#CD012197-bbs2-0100" title="GerrardP , MalcolmR . Mechanisms of modafinil: A review of current research. Neuropsychiatric Disease and Treatment2007;3(3):349‐64. ">Gerrard 2007</a>). Among other actions, methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopaminergic transporter and carrier proteins (<a href="./references#CD012197-bbs2-0164" title="VolkowND , FowlerJS , WangG , DingY , GatleySJ . Mechnism of action of methylphenidate: Insights from PET imaging studies. Journal of Attention Disorders2002;6(1):S31‐S43. ">Volkow 2002</a>). </p> <section id="CD012197-sec-0076"> <h6 class="title">Methylphenidate</h6> <p>Three placebo‐controlled studies have investigated the efficacy of methylphenidate for the treatment of apathy in people with AD (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>; <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>). These studies had similar eligibility criteria, with participants having mild‐to‐moderate AD and clinically significant apathy at baseline. In all three studies, the daily target dose of methylphenidate was 20 mg. </p> <p><a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> conducted a cross‐over study with two two‐week treatment phases and a one‐week placebo washout between treatment phases. The authors reported no treatment order or carry‐over effects. We extracted paired data from this study. We did not consider the cross‐over design to be a source of bias. </p> <p><a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> and <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> both used a parallel‐group design and investigated the efficacy and safety of methylphenidate in the treatment of apathy over six and 12 weeks respectively. </p> </section> <section id="CD012197-sec-0077"> <h6 class="title">Modafinil</h6> <p><a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> also investigated the effect of modafinil on apathy in people with mild‐to‐moderate AD and clinically significant apathy at baseline (FrSBe apathy Tscore ≥ 65). As <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> provided the baseline and final standard deviation (SD) values, we imputed the change SD using methodology provided in the <i>Cochrane Handbook</i> (Section 16.1.3.2). </p> </section> </section> <section id="CD012197-sec-0078"> <h5 class="title">Objective 2:</h5> <p>Seventeen studies reported the effect of a pharmacotherapy on apathy as a secondary outcome measure. The drugs studied were cholinesterase inhibitors (ChEIs), atypical antipsychotics, antidepressants, mibampator, valproate and semagacestat, versus placebo. Two placebo‐controlled discontinuation studies with ChEIs and antipsychotics also investigated apathy as a secondary outcome measure. Clinically significant apathy was not an inclusion criterion in any of the studies. </p> <section id="CD012197-sec-0079"> <h6 class="title">Cholinesterase inhibitors</h6> <p>Six studies investigating ChEIs met the inclusion criteria for this review. Two studies (<a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a>; <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a>) included participants with moderate‐to‐severe AD. <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a>; <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>; <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a>; and <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> included participants with mild‐to‐moderate AD. Although none of the studies actively recruited participants with clinically significant apathy (considered as an NPI apathy subscore ≥ 3), baseline apathy in the <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> was clinically significant in both treatment groups. In the remaining studies, neither treatment group had clinically significant apathy at baseline. </p> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a>, the <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> and <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> included currently approved ChEIs for the treatment of AD (donepezil, galantamine and rivastigmine). </p> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a> and the <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> investigated the efficacy and safety of donepezil (target dose: 5 ‐ 10 mg/daily) over 24 weeks. Both papers reported change scores as least square mean (LSM) change. We considered this to be a potential source of selective reporting bias, as covariates were included in a linear regression which computed adjusted mean change values. We computed the SD values from the provided standard error (SE) values for LSM change using methods provided in the <i>Cochrane Handbook</i> (Section 7.7.3.2). </p> <p><a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> reported the effect of galantamine on neuropsychiatric symptoms (NPS) in a post hoc analysis of pooled data from three large trials (<a href="./references#CD012197-bbs2-0159" title="TariotPN , SolomonPR , MorrisJC , KershawP , LilienfeldS , DingC . A 5‐month, randomized, placebo‐controlled trial of galantamine in AD. The Galantamine USA‐10 Study Group. Neurology2000;54(12):2269‐76. ">Tariot 2000</a>; <a href="./references#CD012197-bbs2-0146" title="RockwoodK , MintzerK , TruyenL , WesselT , WilkinsonD . Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial.. Journal of Neurology, Neurosurgery and Psychiatry2001;71(5):589‐95. ">Rockwood 2001</a>; data file from Janssen‐Ortho) which had study durations of three, five and six months, respectively. We included data from this post hoc analysis because each trial met inclusion criteria for this meta‐analysis, and because we were unable to obtain sufficient data from the primary papers. <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> conducted an ITT analysis on the pooled data obtained from the last observation on each participant. </p> <p><a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>, <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a>, and <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> all investigated the efficacy and safety of metrifonate in AD. Metrifonate is an irreversible organophosphate acetylcholinesterase inhibitor which was not approved for the symptomatic management of AD. All three papers reported LSM change scores which used covariates to create an adjusted mean change score. Again, we considered this to be a potential source of selective reporting bias. We were able to compute SD change values from <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> using reported SE change values. However, as neither <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> nor <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> reported SE or SD change values, we used SD values computed from <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> for both these studies, as all studies had participants with similar AD severity, and the same study duration and dosing regimen. </p> </section> <section id="CD012197-sec-0080"> <h6 class="title">ChEI discontinuation</h6> <p><a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> investigated the efficacy and safety of ChEI discontinuation in people with moderate to severe AD. Continuing treatment with a ChEI was compared to ChEI discontinuation (placebo substitution), and so we included the results of this study in the meta‐analysis. However, this evidence is indirect in terms of our review questions, as all participants were receiving long‐term ChEI treatment (more than a year) prior to study enrollment, and it is unclear how this may influence our findings. Although <a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> did not actively recruit participants with clinically significant apathy, those who were randomized to continue ChEI use had clinically significant apathy (NPI‐apathy subscale score ≥ 3) compared to placebo. However, the difference between groups was not statistically significant. </p> </section> <section id="CD012197-sec-0081"> <h6 class="title">Atypical antipsychotics</h6> <p>We identified 16 RCTs that evaluate the efficacy of atypical antipsychotics for aggression and psychosis in people with AD (<a href="./references#CD012197-bbs2-0069" title="BallardC , WaiteJ , Birks . Atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2; PUBMED: 16437455] ">Ballard 2006</a>). However, only two of these studies met our inclusion criteria and reported sufficient data on apathy, or provided data upon request, for this meta‐analysis (<a href="https://www.archie.cochrane.org/sections/documents/view?version=z1706301610118665211866245036658%26format=REVMAN#STD-De-Deyn-2004" target="_blank">De Deyn 2004</a>; <a href="https://www.archie.cochrane.org/sections/documents/view?version=z1706301610118665211866245036658%26format=REVMAN#STD-Sultzer-2008" target="_blank">Sultzer 2008</a>).<br/> <br/> <a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> investigated the efficacy of olanzapine versus placebo in treating NPS over 10 weeks. As participants in this study were randomized into one of five groups (1, 2.5, 5 or 7.5 mg of olanzapine, or placebo), we have combined results from those randomized to olanzapine to prevent a unit‐of‐analysis error due to multiple comparisons (<i>Cochrane Handbook</i> section 16.5.4). The method used for combining groups was provided in the <i>Cochrane Handbook</i> (Section 7.7.3.8). As well as meeting standardized criteria for AD, all participants also had clinically significant psychotic symptoms.<br/> <br/> <a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> investigated the efficacy of atypical antipsychotics (olanzapine, quetiapine and risperidone) versus placebo in treating NPS for up to 36 weeks (phase 1 of the study). In phase 2 of the study, participants could be randomized to a different medication at the clinician’s discretion. Mean change scores were reported over the first 12 weeks of phase 1 of the study, and so we used these results in the meta‐analysis. Participants were randomized to one of four groups (olanzapine, quetiapine, risperidone or placebo). In order to prevent a unit‐of‐analysis error due to multiple comparisons, we combined results from participants receiving all three atypical antipsychotics. In addition to meeting standardized criteria for AD, all participants also had clinically significant psychotic symptoms or agitation/aggression over the four weeks prior to study entry. </p> <p>Neither study actively recruited people with clinically significant apathy. However, in <a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> each treatment group had clinically significant apathy at baseline. As <a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> did not provide baseline scores on apathy, we were unable to determine whether participants enrolled in this study had clinically significant apathy. </p> </section> <section id="CD012197-sec-0082"> <h6 class="title">Antipsychotic discontinuation</h6> <p>We identified nine clinical trials which investigated the efficacy and safety of antipsychotic discontinuation in people with AD, but we were able to include only one study which met our inclusion criteria and provided data on apathy upon request (<a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a>). </p> <p><a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> investigated the efficacy of antipsychotic discontinuation in people with AD who had been receiving haloperidol, risperidone or olanzapine (range: 3 to 62 months). Neither treatment group had clinically significant apathy at baseline. </p> </section> <section id="CD012197-sec-0083"> <h6 class="title">Antidepressants</h6> <p>We identified 12 trials comparing antidepressants with placebo in people with AD. However, only two studies met our inclusion criteria and yielded extractable data (<a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a>) or provided data upon request (<a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a>). </p> <p><a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> investigated the effect of sertraline on NPS in people with severe AD and clinically significant NPS (NPI ≥ 8). This cross‐over study consisted of two four‐week treatment phases separated by a one‐week placebo washout. Neither treatment group had clinically significant apathy at baseline. As the authors reported that treatment order did not have an effect on treatment response, we did not consider the cross‐over design to be a source of bias. <a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> published results in treatment responders only, but data on all participants were provided upon request. </p> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> investigated the effect of citalopram on agitation in people with AD and clinically significant agitation over nine weeks. As <a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> provided median and interquartile range (IQR) values for NPI‐apathy subscores and NPI‐total scores, we used methods described in the <i>Cochrane Handbook</i> (Section 7.7.3.5) to validate use of the median to estimate mean values, and to convert IQR to SD values. For mini‐mental state examination (MMSE) and Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS‐ADL) scores, SD values were provided at baseline, while SE values were provided at study endpoint. We calculated the SD from SE values using methods provided in the <i>Cochrane Handbook</i> (Section 7.7.3.2), and derived change SD values also using methods provided in the <i>Cochrane Handbook</i> (Section 16.1.3.2). </p> <p>The presence of clinically significant apathy was not an inclusion criterion for either study. However, participants in <a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> had clinically significant apathy (NPI‐apathy subscore ≥ 3) at baseline. </p> </section> <section id="CD012197-sec-0084"> <h6 class="title">Mibampator</h6> <p><a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> investigated the efficacy of mibampator (LY451396) on agitation/aggression in people with AD over 12 weeks. <a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> reported the LSM change score and SD for overall behavior using the FrSBe total Tscore. Apathy was assessed using the FrSBe apathy T‐subscore. We extrapolated the LSM change score for apathy from a graph. However, as SD change scores for apathy were not provided in the paper, we inferred these values from the FrSBe total change Tscore results. As LSM change scores use covariates to create an adjusted mean change score, we considered this as a potential source of selective reporting bias. Since <a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> did not provide baseline apathy scores, we were unable to determine whether study participants had clinically significant apathy. </p> </section> <section id="CD012197-sec-0085"> <h6 class="title">Valproate</h6> <p>We identified three studies investigating valproate which met the inclusion criteria for this meta‐analysis (<a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a>; <a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a>; <a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a>). These studies had similar eligibility criteria, with participants having moderate AD and clinically significant agitation/aggression. <a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> also included participants with clinically significant psychosis. In all three studies, the primary outcome measure was the efficacy of valproate on agitation/aggression (and/or psychosis in <a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a>).<br/> <br/> <a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> was a cross‐over study with two six‐week treatment phases separated by a two‐week placebo washout period. Data from this study were provided upon request. Though <a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> did not actively recruit people with clinically significant apathy, those randomized to receive placebo had clinically significant apathy (NPI‐apathy subscale score ≥ 3) compared to those receiving valproate. However, the difference between groups was not statistically significant.<br/> <br/> <a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> was also a cross‐over study with two three‐week treatment phases separated by a one‐week placebo washout period. We were unable to confirm whether participants enrolled in this study had clinically significant apathy at baseline.<br/> <br/> Although treatment order and carry‐over effects were investigated by <a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> and <a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a>, both papers reported the absence of these effects. As such, we did not consider the cross‐over design to be a source of bias. We extracted paired data from both studies. </p> <p><a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> investigated the efficacy of valproate as a prophylactic treatment for emerging agitation or psychosis in people with moderate AD over 24 months, followed by a two‐month period of single‐blind placebo treatment. Neither treatment group had clinically significant apathy. Data from this study were provided by the Alzheimer's Disease Cooperative Study (ADCS) group upon request. </p> </section> <section id="CD012197-sec-0086"> <h6 class="title">Semagecestat</h6> <p><a href="./references#CD012197-bbs2-0147" title="RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease : JAD2016;54(1):373‐81. [PUBMED: 27567808] ">Rosenberg 2016</a> investigated the efficacy of semagecestat for the treatment of AD over 76 weeks. Participants in this study were randomized to one of three groups (100 or 140 mg of semagacestat, or placebo). We combined results from those randomized to both semagacestat groups using the method provided in the <i>Cochrane Handbook</i> (Section 7.7.3.8) in order to prevent a unit‐of‐analysis error due to multiple comparisons (<i>Cochrane Handbook</i> Section 16.5.4). We used methods described in the <i>Cochrane Handbook</i> (Section 7.7.3.2) to calculate SD values for the MMSE and ADCS‐ADL scores from the 95% confidence intervals reported by the authors. </p> <p>We were unable to confirm whether participants enrolled in this study had clinically significant apathy, as neither <a href="./references#CD012197-bbs2-0090" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] ">Doody 2013</a> nor <a href="./references#CD012197-bbs2-0147" title="RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease : JAD2016;54(1):373‐81. [PUBMED: 27567808] ">Rosenberg 2016</a>, who published the original findings of the study, provided baseline apathy scores. </p> </section> </section> <section id="CD012197-sec-0087"> <h5 class="title">Interventions</h5> <p>We present relevant details about treatment groups and doses of medication used in each study in <a href="#CD012197-tbl-0003">Table 1</a>. </p> </section> <section id="CD012197-sec-0088"> <h5 class="title">Outcomes</h5> <p>All trials included in this meta‐analysis examined apathy as a primary or secondary outcome measure. We summarize the details of outcomes measured and reported in each trial in <a href="#CD012197-tbl-0004">Table 2</a>. A number of scales were used to measure each outcome. </p> <div class="table" id="CD012197-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome Measures and Assessments</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Apathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global Change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dropouts due to AEs reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>METHYLPHENIDATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Informant<br/> <br/> NPI‐apathy subscale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Informant<br/> <br/> NPI‐apathy subscale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐total (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Clinician</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<br/> IADL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MODAFINIL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FrSBe‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADLQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>CHOLINESTERASE INHIBITORS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="6" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>CHOLINESTERASE DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ATYPICAL ANTIPSYCHOTICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="2" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS‐withdrawn depression factor score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ANTIPSYCHOTIC DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ANTIDEPRESSANTS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="2" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>MIBAMPATOR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FrSBe‐apathy T score</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>VALPROATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GIP‐apathetic behavior subscore</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>SEMAGACESTAT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0016" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease2016;54(1):373‐81. [PUBMED: 27567808] ">Semgacestat trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADCS‐CGIC: Alzheimer's Diserase Cooperative Study ‐ Clinical Global Impression of Change, ADL: Activities of Daily Living scale, ADLQ: Lawton and Brody Fucntional Assessment, AES: Apathy Evaluation Scale, CGI‐C: Clinical Global Impression of Change, FrSBe: Frontal Systems Behavior Scale, GIP: The Behavior Observation Scale for Intramural Psychogeriatric Patients, IADL: Instrumental Activities of Daily Living Scale, MMSE: Mini‐Mental State Examination, NPI: Neuropsychiatric Inventory. </p> </div> </div> </section> <section id="CD012197-sec-0089"> <h5 class="title">Primary efficacy and safety outcomes:</h5> <section id="CD012197-sec-0090"> <h6 class="title">1) Apathy</h6> <p><b>NPI‐apathy subscale:</b> Apathy is a subscale item on the NPI scale. The apathy score is calculated as the product of frequency and severity of apathy symptoms, with a range of 0 to 12. Higher scores indicate more frequent and/or severe symptoms (<a href="./references#CD012197-bbs2-0080" title="CummingsJL , MegaM , GrayK , Rosenberg‐ThompsonS , CarusiDA , GornbeinJ . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology1994;44(12):2308‐14. [PUBMED: 7991117] ">Cummings 1994</a>).<br/> <b>AES‐Informant (AES‐I) and AES‐Clinician (AES‐C):</b> This is an 18‐item informant (AES‐I) or clinician (AES‐C)‐rated scale which measures apathy severity as defined by simultaneous deficits in the overt behavioral, cognitive and emotional constructs of goal‐directed behavior. The higher the score, the greater the apathy severity (<a href="./references#CD012197-bbs2-0129" title="MarinRS , BiedrzyckiRC , FirinciogullariS . Reliability and validity of the apathy evaluation scale. Psychiatry Research1991;38(2):143‐62. [PUBMED: 1754629] ">Marin 1991</a>). <br/> <b>BPRS Withdrawn depression factor score:</b> The Withdrawn Depression component of the BPRS consists of emotional withdrawal, depressed mood, motor retardation, and blunted affect (<a href="./references#CD012197-bbs2-0137" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;19:799‐812. ">Overall 1962</a>). This component of the BPRS has been shown to be fairly associated with scores on the NPI‐apathy subscale (<a href="./references#CD012197-bbs2-0140" title="PolitisAM , MayerLS , PassaM , MaillisA , LyketsosCG . Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H‐NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic. International Journal of Geriatric Psychiatry2004;19(3):203‐8. [PUBMED: 15027034] ">Politis 2004</a>).<br/> <b>FrSBE apathy:</b> Apathy is a subscale item on the FrSBE, which measures three frontal systems behavioral syndromes: apathy, disinhibition, and executive dysfunction. The higher the score, the greater the severity of apathy (<a href="./references#CD012197-bbs2-0102" title="GraceJ . Frontal systems behavior scale. Encyclopedia of Clinical Neuropsychology2011:1090‐3. ">Grace 2011</a>).<br/> <b>Behavior Rating Scale for Psychogeratric Inpatients (GIP):</b> Apathy is one of four components of the 82‐item GIP scale. Higher scores indicate greater severity of apathy (<a href="./references#CD012197-bbs2-0089" title="DiesfeldtHF . Interpreting change scores of the Behavioural Rating Scale for Geriatric Inpatients (GIP). Tijdschrift voor Gerontologie en Geriatrie2013;44(4):166‐74. [PUBMED: 23921986] ">Diesfeldt 2013</a>). </p> </section> <section id="CD012197-sec-0091"> <h6 class="title">2) Adverse events</h6> <p>As a number of drug classes were included in this meta‐analysis, we chose to use the number of participants who experienced one or more adverse events (AEs) as an indication of safety. This outcome was reported by all studies which reported safety outcomes. </p> </section> </section> <section id="CD012197-sec-0092"> <h5 class="title">Secondary outcomes:</h5> <section id="CD012197-sec-0093"> <h6 class="title">3) NPS</h6> <p><b>NPI:</b> The NPI is a widely‐used assessment of 12 behavioral symptoms in dementia, including: delusions, hallucinations, agitation/aggression, apathy, depression, euphoria, aberrant motor behavior, irritability, disinhibition, anxiety, sleeping and eating. The frequency and severity of these symptoms are judged on a four‐point and three‐point scale, respectively (<a href="./references#CD012197-bbs2-0080" title="CummingsJL , MegaM , GrayK , Rosenberg‐ThompsonS , CarusiDA , GornbeinJ . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology1994;44(12):2308‐14. [PUBMED: 7991117] ">Cummings 1994</a>). </p> </section> <section id="CD012197-sec-0094"> <h6 class="title">4) Cognition</h6> <p><b>MMSE:</b> This scale measures global cognition, and assesses orientation to time and place, immediate recall, short‐term verbal memory, calculation, language, and construct ability. The MMSE is scored out of 30, with lower scores indicating greater cognitive impairment (<a href="./references#CD012197-bbs2-0095" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12(3):189‐98. [PUBMED: 1202204] '>Folstein 1975</a>). </p> </section> <section id="CD012197-sec-0095"> <h6 class="title">5) Function</h6> <p><b>IADL scale/ADL‐Q:</b> Although termed differently by <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> and <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>, the scale used was the same between both studies. This questionnaire measures functional abilities in elderly people necessary for independent living. Scores range from 0 to 28, with lower scores indicating greater functional impairment (<a href="./references#CD012197-bbs2-0123" title="LawtonMP , BrodyEM . Assessment of older people: self‐maintaining and instrumental activities of daily living. Gerontologist1969;9(3):179‐86. [PUBMED: 5349366] ">Lawton 1969</a>).<br/> <br/> <b>ADL scale:</b> This questionnaire assesses independence in performing basic tasks such as bathing, dressing, and feeding. Scores range from 0 to 24, with lower scores indicating greater functional impairment (<a href="./references#CD012197-bbs2-0115" title="KatzS , FordAB , MoskowitzRW , JacksonBA , JaffeMW . Studies of illness in the aged. The index of ADL: A standardized measure of biological and psychosocial function. JAMA1963;185:914‐9. [PUBMED: 14044222] ">Katz 1963</a>). </p> </section> <section id="CD012197-sec-0096"> <h6 class="title">6) Global change</h6> <p><b>CGIC and ADCS‐CGIC:</b> This scale quantifies disease severity and clinical change (worsening, no change, or improvement), based on information about the person’s medical history, cognition, behavior, and function (<a href="./references#CD012197-bbs2-0149" title="SchneiderLS , OlinJT , DoodyRS , ClarkCM , MorrisJC , ReisbergB , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S22‐32. [PUBMED: 9236949] ">Schneider 1997</a>). </p> </section> <section id="CD012197-sec-0097"> <h6 class="title">7) Dropouts due to AEs</h6> <p>In clinical trials with AD participants, attrition is a common problem attributed to loss to follow‐up, lack of efficacy, violation of study protocol, and the presence of AEs. As we are concerned with tolerability, we report on the number of dropouts due to an AE. </p> </section> </section> </section> <section id="CD012197-sec-0098"> <h4 class="title">Excluded studies</h4> <p>Double‐blind, placebo‐controlled RCTs which we exclude from this meta‐analysis are presented in the <a href="./references#CD012197-sec-0163" title="">Characteristics of excluded studies</a>. We did not exclude any RCTs which investigated and reported on the efficacy of a pharmacological intervention on apathy as a primary or secondary outcome measure in people with mild, moderate, or severe AD. </p> </section> </section> <section id="CD012197-sec-0099"> <h3 class="title">Risk of bias in included studies</h3> <p>All studies included in this meta‐analysis were described as double‐blind, randomized, placebo‐controlled trials. We present details concerning the risks of bias of individual studies in the <a href="./references#CD012197-sec-0162" title="">Characteristics of included studies</a> tables; <a href="#CD012197-fig-0002">Figure 2</a>; and <a href="#CD012197-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012197-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012197-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012197-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Figure 3   CaptionRisk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012197-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p> Figure 3   CaptionRisk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012197-sec-0100"> <h4 class="title">Allocation</h4> <p>Most trials provided an adequate description of treatment allocation, but for some trials we were unable to obtain or locate this information. In these cases, we indicated unclear bias. These trials included the following: <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>; <a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a>; <a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a>; <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>. </p> </section> <section id="CD012197-sec-0101"> <h4 class="title">Incomplete outcome data</h4> <p>All trials except <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> and <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> adequately described attrition rates in text, or included a figure detailing participant flow, or both. As mentioned previously, <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> investigated the efficacy of galantamine in a pooled post hoc analysis of three placebo‐controlled RCTs. Two of the studies included participant flow diagrams, and described study discontinuations in detail (<a href="./references#CD012197-bbs2-0159" title="TariotPN , SolomonPR , MorrisJC , KershawP , LilienfeldS , DingC . A 5‐month, randomized, placebo‐controlled trial of galantamine in AD. The Galantamine USA‐10 Study Group. Neurology2000;54(12):2269‐76. ">Tariot 2000</a>; <a href="./references#CD012197-bbs2-0146" title="RockwoodK , MintzerK , TruyenL , WesselT , WilkinsonD . Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial.. Journal of Neurology, Neurosurgery and Psychiatry2001;71(5):589‐95. ">Rockwood 2001</a>). In <a href="./references#CD012197-bbs2-0146" title="RockwoodK , MintzerK , TruyenL , WesselT , WilkinsonD . Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial.. Journal of Neurology, Neurosurgery and Psychiatry2001;71(5):589‐95. ">Rockwood 2001</a>, discontinuations due to AEs were more common in participants who were randomized to galantamine than placebo. However, the authors used ITT analyses, and last observation carried forward (LOCF) analysis as appropriate. <a href="./references#CD012197-bbs2-0159" title="TariotPN , SolomonPR , MorrisJC , KershawP , LilienfeldS , DingC . A 5‐month, randomized, placebo‐controlled trial of galantamine in AD. The Galantamine USA‐10 Study Group. Neurology2000;54(12):2269‐76. ">Tariot 2000</a> reported that discontinuations due to AEs were similar between participants randomized to galantamine compared to placebo. We considered that these two studies had a low risk of attrition bias. However, as <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> was not able to confirm whether this also applied to data obtained from Janssen‐Ortho, this was a potential source of bias.<br/> <br/> In <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>, authors mention that reported data included LOCF analysis in an ITT population. However, as no further details on attrition were provided, we included this as a potential source of bias. </p> </section> <section id="CD012197-sec-0102"> <h4 class="title">Selective reporting</h4> <p>As mentioned previously in the <a href="#CD012197-sec-0072">Description of studies</a>, we had concerns with selective reporting, specifically in studies comparing ChEI, citalopram and semagacestat versus placebo. In <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>, <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a>, <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a>, and the <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a>, change scores were reported as LSM values. As LSM values use covariates to generate an adjusted mean change score, this is a possible source of selective reporting bias. </p> <p><a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> and the <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> both reported SE values of LSM change scores. We were able to compute SD values from the SE values provided. However, as <a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> and <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> did not report SE or SD values, we used the SD values we had computed from <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a>, as there were similarities across all three studies in AD severity of participants, study duration, and dosing regimen. Again, we considered this to be a possible source of selective reporting bias. </p> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> reported median values for continuous outcome measures. This is a source of selective reporting bias, as <a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> also reported that the data for these measures were not normally distributed, and may not be an accurate representation of the raw mean values.<br/> <br/> <a href="./references#CD012197-bbs2-0147" title="RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease : JAD2016;54(1):373‐81. [PUBMED: 27567808] ">Rosenberg 2016</a> reported on our primary efficacy outcome of apathy, and NPS. </p> </section> </section> <section id="CD012197-sec-0103"> <h3 class="title" id="CD012197-sec-0103">Effects of interventions</h3> <p>See: <a href="./full#CD012197-tbl-0001"><b>Summary of findings for the main comparison</b> Methylphenidate compared to placebo for apathy in Alzheimer's disease</a>; <a href="./full#CD012197-tbl-0002"><b>Summary of findings 2</b> Modafinil compared to placebo for apathy in Alzheimer's disease</a> </p> <section id="CD012197-sec-0104"> <h4 class="title">Objective 1:</h4> </section> <section id="CD012197-sec-0105"> <h4 class="title">Comparison of methylphenidate with placebo</h4> <p>See: <a href="./full#CD012197-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012197-sec-0106"> <h5 class="title">Primary efficacy and safety outcomes:</h5> <section id="CD012197-sec-0107"> <h6 class="title">1. Apathy</h6> <p>Three included studies investigated and reported on the efficacy of methylphenidate for the treatment of apathy as a primary outcome measure (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>; <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>). All studies used the AES to assess apathy. <a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> and <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> also used the NPI‐apathy subscale. We conducted separate analyses using results from the AES scale, and results from the NPI‐apathy subscale. </p> <section id="CD012197-sec-0108"> <p><b>Apathy assessed by the AES:</b></p> <p>Based on findings obtained from the AES, we found that methylphenidate may improve apathy compared to placebo (mean difference (MD) ‐4.99, 95% confidence interval (CI) ‐9.55 to ‐0.43, P = 0.03, n = 145, 3 studies, I<sup>2</sup> = 83%). However, there was uncertainty associated with this result, which we considered to be of low quality, because of serious concerns with inconsistency due to substantial heterogeneity, and imprecision due to a wide 95% confidence interval. </p> <p>We conducted an exploratory subgroup analysis in studies with a trial duration of less than 12 weeks, and studies with a trial duration of 12 weeks or more. We had not prespecified this trial duration cut‐off, but chose this duration based on visual inspection of the forest plot which suggested that <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> had a greater change in apathy scores than <a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> and <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>, despite having similar participant characteristics and dosing (<a href="#CD012197-tbl-0003">Table 1</a>). In studies lasting less than 12 weeks, methylphenidate may improve apathy compared to placebo (MD ‐2.62, 95% CI ‐4.80 to ‐0.44, P = 0.02, n = 85, 2 studies, I<sup>2</sup> = 0%). In <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>, the only study with a trial duration longer than 12 weeks, methylphenidate may also improve apathy compared to placebo (MD ‐9.90, 95% CI ‐13.50 to ‐6.30, P &lt; 0.001, n = 60, 1 study). Within each subgroup, there was uncertainty associated with the results, which we considered to be of low quality because of serious concerns with indirectness due to nongeneralizability of results, and to imprecision. </p> <p>We noted significant differences between subgroups (Chi<sup>2</sup>(1) = 11.49, P &lt; 0.001, I<sup>2</sup> = 91.3%). Trial duration is one possible explanation for the difference identified between subgroups. See <a href="./references#CD012197-fig-0007" title="">Analysis 1.1</a>; <a href="#CD012197-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD012197-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 7 Methylphenidate, outcome: 7.1 Apathy (AES only)." data-id="CD012197-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 7 Methylphenidate, outcome: 7.1 Apathy (AES only).</p> </div> </div> </div> <p>We could not conduct a subgroup analysis by disease severity, as all three studies enrolled participants with similar AD severity. </p> </section> <section id="CD012197-sec-0109"> <p><b>Apathy assessed by the NPI‐apathy subscale:</b></p> <p>Based on findings obtained from the NPI‐apathy subscale, we found that methylphenidate may have no effect on apathy (MD ‐0.08, 95% CI ‐3.85 to 3.69, P = 0.97, n = 85, 2 studies I<sup>2</sup> = 84%). There was uncertainty associated with this result, which we considered to be of low quality because of serious concerns with inconsistency due to substantial heterogeneity, and to imprecision due to a wide 95% confidence interval which may have contributed to an overall null effect. See <a href="./references#CD012197-fig-0008" title="">Analysis 1.2</a>. </p> <p>As we included only two studies in this meta‐analysis, we did not conduct additional subgroup analyses. </p> </section> </section> <section id="CD012197-sec-0110"> <h6 class="title">2. Adverse events</h6> <p>Although <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> reported that there were trends towards increased anxiety and weight loss (&gt; 2%) in those allocated to methylphenidate, there was little or no difference between treatment groups in the risk of developing an AE (RR 1.28, 95% CI 0.67 to 2.42, P = 0.45, n = 145, 3 studies, I<sup>2</sup> = 62%). There was uncertainty associated with this result, which we considered to be of low quality due to serious concerns with inconsistency and imprecision. </p> <p>An exploratory subgroup analysis demonstrated that there was probably little or no difference between treatment groups in the risk of developing an AE in trials with a duration of less than 12 weeks (RR 1.28, 95% CI 0.44 to 3.72, P = 0.65, n = 85, 2 studies, I<sup>2</sup> = 38%), or in trials of 12 weeks or longer (RR 1.44, 95% CI 0.73 to 2.86, P = 0.29, n = 60, 1 study). Within each subgroup, there was uncertainty associated with the results, which we considered to be of low quality because of serious concerns with indirectness due to nongeneralizability of results, and to imprecision.<br/> <br/> There were no significant differences noted between subgroups (Chi<sup>2</sup>(1) = 0.03, P = 0.85, I<sup>2</sup> = 0%). See <a href="./references#CD012197-fig-0009" title="">Analysis 1.3</a>; <a href="#CD012197-fig-0005">Figure 5</a>.<br/> <br/> We did not conduct a subgroup analysis based on disease severity, as all three studies enrolled participants with similar AD severity. </p> <div class="figure" id="CD012197-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 7 Methylphenidate, outcome: 7.3 Adverse Events." data-id="CD012197-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 7 Methylphenidate, outcome: 7.3 Adverse Events.</p> </div> </div> </div> </section> </section> <section id="CD012197-sec-0111"> <h5 class="title">Secondary outcomes:</h5> <section id="CD012197-sec-0112"> <h6 class="title">3. Neuropsychiatric symptoms</h6> <p>Only one study investigated and reported on the change in NPS over study duration (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>). There may be little or no difference between treatment groups in the change in NPI total score over two weeks (MD 0.16, 95% CI ‐7.89 to 8.21, P = 0.97, n = 25, 1 study). There was uncertainty associated with this result, which we considered to be of low quality because of serious concerns with imprecision, as there was a wide 95% confidence interval, which may have contributed to the overall null effect, in a single study with a small sample size. See <a href="./references#CD012197-fig-0010" title="">Analysis 1.4</a>. </p> </section> <section id="CD012197-sec-0113"> <h6 class="title">4. Cognition</h6> <p>All studies assessed change in cognition using the MMSE. Compared to placebo, methylphenidate probably improves cognition slightly, although this difference may not be large enough to be of clinical importance (MD 1.98, 95% CI 1.06 to 2.91, P &lt; 0.0001, n = 145, 3 studies, I<sup>2</sup> = 37%). We considered this evidence to be of moderate quality, because of serious concerns with imprecision due to a wide 95% confidence interval.<br/> <br/> An exploratory subgroup analysis in studies by trial duration demonstrated that there was probably little or no difference between treatment groups on change in cognition over time in trials with a duration of less than 12 weeks (MD 1.00, 95% CI ‐0.49 to 2.49, P = 0.19, n = 85, 2 studies, I<sup>2</sup> = 0%). In <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>, the only study with a trial duration longer than 12 weeks, methylphenidate probably improves cognition compared to placebo (MD 2.60, 95% CI 1.43 to 3.77, P &lt; 0.001, n = 60, 1 study). We rated the evidence for both subgroup analyses as of moderate quality, because of serious concerns with imprecision due to a wide 95% confidence interval. </p> <p>We found no significant differences between subgroups (Chi<sup>2</sup>(1) = 2.74, P = 0.10, I<sup>2</sup>= 63.5%).See <a href="./references#CD012197-fig-0011" title="">Analysis 1.5</a>. </p> <p>We did not conduct a subgroup analysis based on disease severity, as all three studies enrolled participants with similar AD severity. </p> </section> <section id="CD012197-sec-0114"> <h6 class="title">5. Functional performance</h6> <p>Only one study reported on the change in functional performance using the ADL and IADL (<a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>). There was no evidence of a difference between methylphenidate and placebo ADLs over 12 weeks: MD 0.50, 95% CI ‐0.39 to 1.39, P = 0.27, n = 60 patients, 1 study. See <a href="./references#CD012197-fig-0012" title="">Analysis 1.6</a>. However, compared to placebo, methylphenidate probably improves IADLs over 12 weeks: MD 2.30, 95% CI 0.74 to 3.86, P = 0.004, n = 60 patients, 1 study. There was some uncertainty associated with both findings, which we considered to be of moderate quality, as only one study with a small sample size was included in these comparisons. See <a href="./references#CD012197-fig-0013" title="">Analysis 1.7</a>. </p> </section> <section id="CD012197-sec-0115"> <h6 class="title">6. Global disease severity</h6> <p>Two studies reported on global disease severity, measured with the CGI. This was expressed in both studies as the number of participants who experienced clinical deterioration over the course of the study (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>; <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>). There was probably little or no difference between treatment groups in the number who experienced clinical deterioration (RR 0.58, 95% CI 0.16 to 2.11, P = 0.40, n = 85, 2 studies I<sup>2</sup> = 0%). We considered this evidence to be of moderate quality, because of serious concerns with imprecision due to a wide 95% confidence interval. See <a href="./references#CD012197-fig-0014" title="">Analysis 1.8</a>. </p> </section> <section id="CD012197-sec-0116"> <h6 class="title">7. Dropouts due to AEs</h6> <p>There may be little or no difference between treatment groups in the number of dropouts due to an AE (RR 2.18, 95% CI 0.64 to 7.45, P = 0.21, n = 145, 3 studies, I<sup>2</sup> = 0%). There was low certainty associated with this result, which we considered to be of low quality due to serious concerns about imprecision. See <a href="./references#CD012197-fig-0015" title="">Analysis 1.9</a>. </p> </section> </section> </section> <section id="CD012197-sec-0117"> <h4 class="title">Comparison of modafinil with placebo</h4> <p>See: <a href="./full#CD012197-tbl-0002">summary of findings Table 2</a>. Only one very small study (n = 23 randomized, 1 participant excluded from analysis due to AE related dropout) investigated and reported on the efficacy of modafinil for the treatment of apathy as a primary outcome measure (<a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a>). In all of the following outcomes, there were no concerns with risk of bias, inconsistency or indirectness. However, we had very serious concerns with imprecision due to the small sample size and wide 95% confidence intervals. As such we rated the quality of evidence for all of the outcomes as low. </p> <section id="CD012197-sec-0118"> <h5 class="title">Primary efficacy and safety outcomes:</h5> <section id="CD012197-sec-0119"> <h6 class="title">1. Apathy</h6> <p>Apathy was assessed using the FrSBE apathy subscale. Tscores are converted from raw scores which range from 14 to 70, and there is very limited information available on what constitutes a clinically important difference in score. There was no evidence of a difference between treatment groups in the change in apathy over eight weeks (MD 0.27, 95% CI ‐3.51 to 4.05, P = 0.89, n = 22, 1 study). See <a href="./references#CD012197-fig-0016" title="">Analysis 2.1</a>. </p> </section> <section id="CD012197-sec-0120"> <h6 class="title">2. Adverse events</h6> <p>We did not conduct an analysis for this outcome, as there was only one adverse event reported in the modafinil treatment group and none reported in the placebo group. </p> </section> </section> <section id="CD012197-sec-0121"> <h5 class="title">Secondary outcomes:</h5> <section id="CD012197-sec-0122"> <h6 class="title">3. Neuropsychiatric symptoms</h6> <p>This outcome was not reported by <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a>. </p> </section> <section id="CD012197-sec-0123"> <h6 class="title">4. Cognition</h6> <p>This outcome was not investigated by <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a>. </p> </section> <section id="CD012197-sec-0124"> <h6 class="title">5. Functional performance</h6> <p>There was no evidence of a difference between modafinil and placebo in change in functional status over eight weeks (MD ‐0.54, 95% CI ‐1.40 to 0.32, P = 0.22, n = 22, 1 study). See <a href="./references#CD012197-fig-0017" title="">Analysis 2.2</a>. </p> </section> <section id="CD012197-sec-0125"> <h6 class="title">6. Global disease severity</h6> <p>This outcome was not investigated by <a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a>. </p> </section> <section id="CD012197-sec-0126"> <h6 class="title">7. Dropouts due to AEs</h6> <p>There was one dropout from the modafinil treatment group due to an increase in motor tics, and no dropouts from the placebo arm. We did not conduct an analysis for this outcome, as only one individual in the study experienced an AE. </p> </section> </section> </section> <section id="CD012197-sec-0127"> <h4 class="title">Objective 2:</h4> <p>Included studies of ChEIs, antipsychotics, mibampator and semagacestat were supported by pharmaceutical industry sponsors. Additionally, although a large number of studies with antipsychotics, antipsychotic discontinuation, and antidepressants in AD have been conducted, many of which collected data on NPS including apathy, only a few studies reported this or provided data upon request. We therefore downgraded the overall quality of the evidence due to serious concern about the effect of publication bias. Publication bias was not a concern with studies included in the ChEI comparison, as these trials included a large number of participants, and were less likely to remain unpublished or ignored. Furthermore, these trials may provide a more precise estimate of the treatment effect, whether positive or negative. </p> <p>We also downgraded the overall quality of the evidence due to serious concerns with indirectness, as none of the studies contributing to Objective 2 comparisons actively recruited participants with clinically significant apathy. </p> <p>The evidence provided in this section must therefore be considered of low quality at best. </p> </section> <section id="CD012197-sec-0128"> <h4 class="title">Comparison of cholinesterase inhibitors (ChEIs) with placebo</h4> <p>We included six studies investigating ChEIs for cognition in people with AD, that also included apathy as a secondary outcome measure in this meta‐analysis. All six studies used the NPI‐apathy subscale to assess apathy. </p> <p>ChEIs may slightly improve apathy compared to placebo (MD ‐0.40, 95% CI ‐0.80 to ‐0.00, P = 0.05, n = 3598, 6 studies, I<sup>2</sup>= 71%). We considered the available evidence to be of low quality. We downgraded the evidence due to serious concerns with indirectness, inconsistency and selective reporting of adjusted mean values, but upgraded one level due to the large sample size (<a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a>; <a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a>; <a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a>; <a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a>; <a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a>; <a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a>). However, the clinical importance of these findings is uncertain, as apathy was not a primary outcome measure of these studies.<br/> <br/> We conducted subgroup analyses of studies using currently‐approved ChEIs (donepezil, galantamine or rivastigmine), all of which had a duration 24 weeks or less, and studies using metrifonate which all lasted more than 24 weeks. Currently‐approved ChEIs may have little or no effect on apathy compared to placebo (MD ‐0.21, 95% CI ‐0.85 to 0.43, P = 0.29, n = 2531, 3 studies, I<sup>2</sup> = 80%). However, metrifonate may improve apathy compared to placebo (MD ‐0.63, 95% CI ‐0.98 to ‐0.29, P &gt; 0.001, n = 1067, 3 studies, I<sup>2</sup> = 0%). Again, we rated the quality of the evidence as low due to serious concerns with indirectness, and selective reporting of adjusted mean value. There were no significant differences between subgroups (Chi<sup>2</sup>(1) = 1.30, P = 0.25, I<sup>2</sup> = 23.2%). See <a href="./references#CD012197-fig-0018" title="">Analysis 3.1</a>; <a href="#CD012197-fig-0006">Figure 6</a>.<br/> <br/> We also conducted subgroup analyses of studies in which participants had moderate or severe AD. In those with moderate AD, ChEIs may slightly improve apathy compared to placebo (MD ‐0.43, 95% CI ‐0.79 to ‐0.07, P = 0.02, n = 3100, 4 studies, I<sup>2</sup> = 50%). In participants with severe AD, ChEIs may also slightly improve apathy compared to placebo (MD ‐0.36, 95% CI ‐1.82 to 1.10, P = 0.63, n = 498, 2 studies, I<sup>2</sup> = 90%); however this finding was not statistically significant. As mentioned previously, we rated the quality of the evidence as low due to serious concerns with indirectness of the study population, and selective reporting of adjusted mean values. There was no significant difference between subgroups (Chi<sup>2</sup>(1) = 0.01, P = 0.93, I<sup>2</sup> = 0%). See <a href="./references#CD012197-fig-0019" title="">Analysis 3.2</a>. </p> <div class="figure" id="CD012197-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Cholinesterase Inhibitors, outcome: 3.1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs)." data-id="CD012197-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Cholinesterase Inhibitors, outcome: 3.1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs). </p> </div> </div> </div> </section> <section id="CD012197-sec-0129"> <h4 class="title">Comparison of ChEI with ChEI discontinuation (placebo)</h4> <p>Only one study investigating the discontinuation of ChEIs met the inclusion criteria for this meta‐analysis (<a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a>). All participants in this trial were long‐term ChEI users (more than two years), and were considered eligible for this trial if they no longer demonstrated any clinical benefit from their ChEI. </p> <p>Although not statistically significant, discontinuing ChEIs may slightly improve apathy compared to continued ChEI use, based on the NPI‐apathy subscale (MD 1.11, 95% ‐0.88 to 3.10, P = 0.28, n = 40, 1 study). There was some uncertainty associated with this result, which we considered to be of low quality because of serious concerns with imprecision due to the small sample size and wide 95% confidence interval, and indirectness of results.See <a href="./references#CD012197-fig-0020" title="">Analysis 4.1</a>. </p> </section> <section id="CD012197-sec-0130"> <h4 class="title">Comparison of antipsychotics with placebo</h4> <p>All studies in this meta‐analysis that investigated antipsychotics were conducted in people with clinically significant agitation and aggression. We did not perform subgroup analyses by trial duration and disease severity, as only two studies met the inclusion criteria for this particular meta‐analysis.<br/> <br/> <a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> assessed apathy using the NPI‐apathy subscale, while <a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> assessed apathy using the BPRS withdrawn depression factor score. Antipsychotic use may slightly worsen apathy compared to placebo (standardized mean difference (SMD 0.14, 95% CI ‐0.00 to 0.28, P = 0.05, n = 1070, 2 studies, I<sup>2</sup> = 15%). There is some uncertainty associated with this result, which we considered to be of low quality due to serious concerns with indirectness and publication bias. See <a href="./references#CD012197-fig-0021" title="">Analysis 5.1</a>. </p> </section> <section id="CD012197-sec-0131"> <h4 class="title">Comparison of antipsychotics with antipsychotic discontinuation (placebo)</h4> <p>Only one study which investigated the discontinuation of antipsychotics met the inclusion criteria for this meta‐analysis (<a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a>). </p> <p>Continued antipsychotic use may slightly improve apathy on the NPI‐apathy subscale compared to antipsychotic discontinuation (placebo): MD ‐0.24, 95% CI ‐0.51 to 0.03, P = 0.08, n = 55, 1 study. There was uncertainty associated with this result, which we considered to be of low quality due to serious concerns with indirectness and publication bias. Additionally, the clinical importance of these findings is uncertain, as apathy was not a primary outcome measure of these studies. See <a href="./references#CD012197-fig-0022" title="">Analysis 6.1</a>. </p> </section> <section id="CD012197-sec-0132"> <h4 class="title">Comparison of antidepressants with placebo</h4> <p>Two studies with antidepressants met the inclusion criteria for this meta‐analysis (<a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a>; <a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a>). All participants had clinically significant NPS (<a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a>) or agitation (<a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a>) at baseline. Apathy was assessed with the NPI‐apathy subscale. </p> <p>We are uncertain whether antidepressants improved apathy compared to placebo over the duration of treatment (MD ‐1.24, 95% ‐1.44 to ‐1.04, P &lt; 0.00001, n = 126, 2 studies, I<sup>2</sup> = 3%). There was uncertainty associated with this result, which we considered to be of very low quality due to selective reporting (the NPI‐subscores in the <a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> were not normally distributed, and the reported medians were used as an estimate of the sample mean), indirectness of results, and publication bias. See <a href="./references#CD012197-fig-0023" title="">Analysis 7.1</a>. </p> </section> <section id="CD012197-sec-0133"> <h4 class="title">Comparison of mibampator with placebo</h4> <p>Only one study investigated and reported on the efficacy of mibampator for the treatment of apathy (<a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a>). </p> <p>We are uncertain whether mibampator improved apathy, assessed with the FrSBe‐apathy Tscore compared to placebo over the duration of treatment (MD ‐1.20, 95% ‐1.94 to ‐0.46, P = 0.001, n = 132, 1 study). There was uncertainty associated with this result, which we considered to be of very low quality due to selective reporting of adjusted mean values, indirectness of results, and publication bias. See <a href="./references#CD012197-fig-0024" title="">Analysis 8.1</a>. </p> </section> <section id="CD012197-sec-0134"> <h4 class="title">Comparison of valproate with placebo</h4> <p>Three studies investigated and reported on the efficacy of valproate for the treatment of apathy (<a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a>; <a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a>; <a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a>). </p> <p>There may be little or no difference between treatment groups in the change in apathy over the duration of treatment (SMD 0.02, 95% CI ‐0.23 to 0.26, P = 0.88, n = 257, 3 studies, I<sup>2</sup> = 0%). There was uncertainty associated with this result, which we considered to be of low quality due to indirectness and imprecision. See <a href="./references#CD012197-fig-0025" title="">Analysis 9.1</a>. </p> </section> <section id="CD012197-sec-0135"> <h4 class="title">Comparison of semagacestat with placebo</h4> <p>Only one paper (<a href="./references#CD012197-bbs2-0147" title="RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease : JAD2016;54(1):373‐81. [PUBMED: 27567808] ">Rosenberg 2016</a>) reported on the efficacy of semagacestat for the treatment of apathy in a secondary analysis of a previously published trial (<a href="./references#CD012197-bbs2-0016" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease2016;54(1):373‐81. [PUBMED: 27567808] ">Semgacestat trial</a>). </p> <p>Semagacestat may slightly worsen apathy assessed with the NPI subscale compared to placebo over the duration of treatment (MD 0.20, 95% CI 0.15 to 0.25, P &lt; 0.001, n = 939, 1 study), but the effect is probably too small to be of clinical significance. There was some uncertainty associated with this result, which we considered to be of low quality as there were concerns with indirectness of results and publication bias. See <a href="./references#CD012197-fig-0026" title="">Analysis 10.1</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012197-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012197-sec-0136">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012197-sec-0198">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012197-sec-0136"></div> <section id="CD012197-sec-0137"> <h3 class="title" id="CD012197-sec-0137">Summary of main results</h3> <p>The results of this meta‐analysis showed the following main findings:</p> <p> <ul id="CD012197-list-0008"> <li> <p>Methylphenidate may improve apathy compared to placebo, based on AES change scores in people with AD and clinically significant apathy at baseline. However, this finding was not supported by the results on NPI‐apathy subscale change scores. Although this inconsistency may be attributed to differences between the scales, another difference is that the analysis with AE data included three studies and 145 participants (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>; <a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>), whereas the analysis with NPI‐apathy subscale data included only two studies with 85 participants (<a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a>; <a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a>). Subgroup analysis with AE data indicates that the effect size was larger in a 12‐week study than in six‐ and eight‐week studies, but this finding could be due to reasons other than trial duration. Notably, there was uncertainty with these findings, as they were associated with low quality of evidence. Methylphenidate may also improve cognition and function. Both of these findings were associated with moderate quality of evidence, although the difference in cognition was small and as a result may not be clinically significant. There were no significant differences between treatment groups in the risk of developing an AE. </p> </li> </ul> <ul id="CD012197-list-0009"> <li> <p>In people with AD and clinically significant apathy at baseline, low‐quality evidence from one very small study suggested that there was no effect of modafinil on apathy. </p> </li> </ul> </p> <p>All other included studies measured apathy as a secondary outcome. Participants in these studies did not necessarily have clinically significant apathy at baseline. </p> <p> <ul id="CD012197-list-0010"> <li> <p>ChEI use may slightly improve apathy compared to placebo, but there is some uncertainty associated with this result due to low quality of evidence. Furthermore, the clinical importance of this finding is uncertain, as apathy was not a primary outcome measure, and the effect size was small. Significance was maintained and heterogeneity was reduced in studies with metrifonate only. These findings were not replicated in more recent studies with currently‐approved ChEIs. Studies with metrifonate had a longer study duration (more than 24 weeks), and were conducted only in people with mild‐to‐moderate AD. However, as subgroup differences were not significant, we cannot confirm the effect of ChEI type (approved ChEI versus metrifonate) or trial duration on the efficacy of ChEI intervention on apathy. In a subgroup analysis of disease severity, we found similarly‐sized effects in people with moderate and severe AD. However, there is uncertainty associated with this result, due to the low quality of evidence. </p> </li> </ul> <ul id="CD012197-list-0011"> <li> <p>Atypical antipsychotics and semagacestat may slightly worsen apathy compared to placebo. Based on the findings of one antipsychotic discontinuation trial, continued antipsychotic use may slightly improve apathy compared to antipsychotic discontinuation. The clinical importance of this finding is uncertain, as apathy was not a primary outcome measure, and the effect size was small. The findings of one ChEI discontinuation trial indicated that ChEI discontinuation may slightly improve apathy compared to ChEI continuation. These findings were limited by a low quality of evidence. </p> </li> </ul> <ul id="CD012197-list-0012"> <li> <p>Valproate demonstrated little or no difference in apathy. However, these findings were supported by low quality of evidence. </p> </li> </ul> <ul id="CD012197-list-0013"> <li> <p>Our findings on antidepressants and mibampator had very low quality of evidence, due to selective reporting, indirectness of results and publication bias. We are therefore uncertain whether these interventions have any effect on apathy. </p> </li> </ul> </p> </section> <section id="CD012197-sec-0138"> <h3 class="title" id="CD012197-sec-0138">Overall completeness and applicability of evidence</h3> <p>By conducting a meta‐analysis we were able to combine findings from multiple clinical trials to evaluate the efficacy of a number of pharmacological interventions for the treatment of apathy in AD. When evaluating the applicability of this review to the clinical setting, outcome measures, participant characteristics, and treatment duration should be taken into consideration. </p> <p>The studies with modafinil and methylphenidate were directly applicable to our review question. They recruited participants with clinically significant apathy, and included apathy as a primary outcome measure, which was likely chosen prior to designing their respective trials. As such, these trials may have a reduced risk of false‐positive errors resulting from the statistical analysis of many outcomes, and may have a reduced risk of false‐negative errors by providing the foundation for a sample size calculation for an adequately‐powered study (<a href="./references#CD012197-bbs2-0066" title="Andrade2015 . The primary outcome measure and its importance in clinical trials. Journal of Clinical Psychiatry2015;76(10):e1320‐3. ">Andrade 2015</a>). For methylphenidate, we found some data on all of our outcome measures. For modafinil, we found no data on cognition, overall NPS, or global disease severity. </p> <p>All other included studies investigated apathy as a secondary outcome measure. Although this may increase the risk of false‐positive and false‐negative errors, the results of these studies are still of interest given the current absence of approved medications for the treatment of apathy in AD. However, for these interventions, the analyses must be regarded as exploratory. From these studies, we sought data on apathy only. In addition to a standardized diagnosis of AD, studies with antipsychotics, antidepressants, and mibampator also had clinically significant NPS as part of their inclusion criteria; in different studies these were overall NPS burden, agitation/aggression or psychosis. Apathy is one of the most frequently observed NPS in people with mild AD. In the advanced stages of AD, psychosis, agitation and aggression also become more prevalent, but apathy persists. In a systematic review of 59 studies, apathy was reported to be the only NPS with high baseline prevalence, persistence and incidence throughout the course of dementia (<a href="./references#CD012197-bbs2-0161" title="Van derLindeRM , DeningT , StephanBCM , PrinaAM , EvansE , BrayneC . Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. British Journal of Psychiatry2016;209(5):366‐77. ">Van der Linde 2016</a>). Hence, results from these studies may still be applicable, despite participants having NPS other than apathy. Some but not all of the Objective 2 studies did report apathy scores at baseline in their participants, and in several of these apathy was at levels usually regarded as clinically significant. </p> <p>Five comparisons contained more than one study and in these study duration varied. The three methylphenidate studies varied from two to 12 weeks. In studies with ChEIs, study duration varied from 12 to 26 weeks. In studies with atypical antipsychotics, study duration varied from four to 36 weeks. In studies with antidepressants, study duration varied from four to nine weeks. Studies with valproate varied in study duration from 3 weeks to 24 months. We had hoped to explore the effect of treatment duration, but in practice the data offered little opportunity to do this due to the small numbers of studies and participants. </p> <p>For this review, apathy was the only outcome evaluated in Objective 2. However, published systematic reviews of RCTs with ChEIs (<a href="./references#CD012197-bbs2-0074" title="BirksJ . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD005593; PUBMED: 16437532] ">Birks 2006</a>), ChEI discontinuation (<a href="./references#CD012197-bbs2-0136" title="O'ReganJ , LanctôtKL , MazereeuwG , HerrmannN . Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta‐analysis of randomized controlled trials. Journal of Clinical Psychiatry2015;76(11):e1424‐31. [PUBMED: 26646039] ">O'Regan 2015</a>), atypical antipsychotics (<a href="./references#CD012197-bbs2-0069" title="BallardC , WaiteJ , Birks . Atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD003476.pub2; PUBMED: 16437455] ">Ballard 2006</a>), antipsychotic discontinuation (<a href="./references#CD012197-bbs2-0087" title="DeclercqT , PetrovicM , AzermaiM , Vander SticheleR , DeSutterAIM , VanDrielML , et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database of Systematic Reviews2013, Issue 4. [DOI: 10.1002/14651858.CD007726.pub2] ">Declercq 2013</a>), antidepressants (<a href="./references#CD012197-bbs2-0152" title="SeitzDP , AdunuriN , GillSS , GruneirA , HerrmannN , RochonP . Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD008191.pub2; PUBMED: 21328305] ">Seitz 2011</a>), and valproate (<a href="./references#CD012197-bbs2-0127" title="LonerganE , LuxenbergJ . Valproate preparations for agitation in dementia. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003945.pub3; PUBMED: 19588348] ">Lonergan 2009</a>) may provide insight regarding their safety and efficacy in people with AD and apathy. </p> </section> <section id="CD012197-sec-0139"> <h3 class="title" id="CD012197-sec-0139">Quality of the evidence</h3> <p>All the included studies were well conducted and well reported, so that we had few serious concerns about risks of bias. We rated four studies as being at high risk of selective reporting bias because they reported only adjusted and not raw mean scores. </p> <p>For Objective 1, the overall quality of the evidence was low for our primary efficacy outcome and low or moderate for adverse events and our secondary outcomes. This was largely due to imprecision; there were few studies and they were small. There was also inconsistency between the three methylphenidate studies in the effect on apathy. </p> <p>For Objective 2, the nature and quality of the evidence meant that our results must be regarded as exploratory only. Many participants in these studies were recruited due to high levels of NPS other than apathy, or had no particular behavioral problems. Hence these studies addressed our review question indirectly. Furthermore, we were able to obtain data on apathy from only a minority of drug trials in AD which have measured it, raising concerns about publication bias. We also considered some of the results to be affected by imprecision, inconsistency or risk of selective reporting bias. </p> </section> <section id="CD012197-sec-0140"> <h3 class="title" id="CD012197-sec-0140">Potential biases in the review process</h3> <p>Ten out of the 21 studies which we included in our meta‐analysis were pharmaceutical industry‐sponsored studies. This may be a source of publication bias, as it has been reported that pharmaceutical‐industry funding is associated with outcomes that are favorable for the funder (<a href="./references#CD012197-bbs2-0126" title="LexchinJ , BeroLA , DjulbegovicB , ClarkO . Pharmaceutical industry sponsorship and research outcome and quality: systematic review. The British Medical Journal (Clinical research ed.)2003;326(7400):1167‐70. [PUBMED: 12775614] ">Lexchin 2003</a>; <a href="./references#CD012197-bbs2-0073" title="BhandariM , BusseJW , JackowskiD , MontoriVM , SchunemannH , SpragueS , et al. Association between industry funding and statistically significant pro‐industry findings in medical and surgical randomized trials. Canadian Medical Association Journal2004;170(4):477‐80. [PUBMED: 14970094] ">Bhandari 2004</a>; <a href="./references#CD012197-bbs2-0105" title="HeresS , DavisJ , MainoK , JetzingerE , KisslingW , LeuchtS . Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head‐to‐head comparison studies of second‐generation antipsychotics. American Journal of Psychiatry2006;163(2):185‐94. [PUBMED: 16449469] ">Heres 2006</a>). The pharmaceutical industry may not publish negative studies as frequently as positive studies. Publication bias is not necessarily confined to industry‐sponsored trials, as academic researchers may also be more likely to publish positive results, which are more likely to be accepted by editors, reviewed by peers, and more often cited. Clinical trial registries aim to increase transparency and access to information about clinical trials. Although clinical trial registries have been available since 1997, governmental bodies and international organizations have been pushing for the registration and standardization of clinical trial registries since 2005. Since 2008, the revised Declaration of Helsinki has stated that every clinical trial must be registered in a publicly accessible database before recruitment of the first participant (<a href="./references#CD012197-bbs2-0099" title="General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. The Journal of the American College of Dentists2014;81(3):14‐8. [PUBMED: 25951678] ">General Assembly of the World Medical Association</a>). However only 10 of the 21 studies included in this meta‐analysis were published in or after 2008.<br/> <br/> We contacted the authors of the 41 additional studies which met our inclusion criterion of investigating apathy as a primary or secondary outcome measure as they did not provide data on our primary outcome of apathy in an extractable format. However, since we did not receive a response, or since data were no longer available to the authors, we excluded those studies from our meta‐analyses. </p> <p>The NPI‐apathy subscale and the AES are two of the most widely‐used scales in research related to apathy in AD. In this review, 16 studies used the NPI‐apathy subscale, four studies used the AES, two used the FrSBe apathy Tscore, and one study each used the BPRS‐withdrawn depression factor score, and the GIP apathetic behavior subscore. As different scales were used to assess apathy in the studies included in this review, heterogeneity of results is a concern. However, there is no widely‐accepted gold‐standard scale for assessing apathy, and there is still a lack of consensus about the definition and diagnostic criteria for apathy (<a href="./references#CD012197-bbs2-0082" title="CummingsJ , FriedmanJH , GaribaldiG , JonesM , MacfaddenW , MarshL , et al. Apathy in neurodegenerative diseases: recommendations on the design of clinical trials. Journal of Geriatric Psychiatry and Neurology2015;28(3):159‐73. [PUBMED: 25809634] ">Cummings 2015</a>). It is therefore important for future research to focus on validating scales and diagnostic criteria for apathy in AD. This would provide definitive recommendations for future clinical trials on how to appropriately target recipients of pharmacological interventions, and how to assess apathy, which would reduce the heterogeneity between studies. </p> </section> <section id="CD012197-sec-0141"> <h3 class="title" id="CD012197-sec-0141">Agreements and disagreements with other studies or reviews</h3> <p>The results of this meta‐analysis add to the current body of evidence for pharmacological interventions for apathy, as previous reports have been inconclusive in elucidating whether methylphenidate is effective and safe in the treatment of apathy in people with AD.<br/> <br/> In a meta‐analysis conducted by <a href="./references#CD012197-bbs2-0153" title="SepehryAA , SaraiM , HsiungGR . Pharmacological therapy for apathy in Alzheimer's disease: a systematic review and meta‐analysis. Canadian Journal of Neurological Sciences.2017;44(3):267‐75. [PUBMED: 28148339] ">Sepehry 2017</a>, the authors investigated pharmacological therapy for apathy in AD. Fifteen studies were included, and 11 were quantitatively analyzed. Pharmacological agents included ChEIs, memantine and psychostimulants (modafinil and methylphenidate). That review did not find any significant effect of drug over placebo on apathy. However, the authors disclosed that in the absence of descriptive statistics (mean and SD values), they generated effect sizes using P values and sample sizes. If P values were not reported, the authors assumed an alpha of 0.06 for their analyses. This method of data imputation would have likely biased the findings of their results due to a high risk of selective reporting.<br/> <br/> A comprehensive review by <a href="./references#CD012197-bbs2-0104" title="HarrisonF , AertsL , BrodatyH . Apathy in dementia: systematic review of recent evidence on pharmacological treatments. Current Psychiatry Reports2016;18(11):103. [PUBMED: 27726067] ">Harrison 2016</a> evaluated the evidence of pharmacotherapies for apathy from studies since 2013. However, as they did not require trials to be placebo‐controlled, nor treat apathy as a primary or secondary outcome measure, nor have AD as a standardized diagnosis, their findings were not consistent with ours. With respect to ChEIs, <a href="./references#CD012197-bbs2-0104" title="HarrisonF , AertsL , BrodatyH . Apathy in dementia: systematic review of recent evidence on pharmacological treatments. Current Psychiatry Reports2016;18(11):103. [PUBMED: 27726067] ">Harrison 2016</a> reported that previous findings about cognitive enhancers (ChEIs and memantine) were not replicated in more recent studies. This finding was similar to our own, as we found a benefit in the older trials investigating metrifonate, but not with the more recent trials with currently‐approved ChEIs. Additionally, although results with antidepressants were mixed, they found benefits with agomelatine in a non‐placebo‐controlled RCT (<a href="./references#CD012197-bbs2-0078" title="CallegariI , MatteiC , BenassiF , KruegerF , GrafmanJ , YaldizliO , et al. Agomelatine Improves apathy in frontotemporal dementia. Neuro‐Degenerative Diseases2016;16(5‐6):352‐6. [PUBMED: 27229348] ">Callegari 2016</a>). Their findings with methylphenidate were inconclusive, but they only included one study (<a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>). We reported on the efficacy of methylphenidate on apathy in three trials. However, as we did not have high‐quality evidence, we suggest that further studies investigating the efficacy of methylphenidate on apathy in people with AD would increase the quality of evidence and strengthen this finding. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012197-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="2Study flow diagram." data-id="CD012197-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>2Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012197-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Figure 3   CaptionRisk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012197-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p> Figure 3   CaptionRisk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 7 Methylphenidate, outcome: 7.1 Apathy (AES only)." data-id="CD012197-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 7 Methylphenidate, outcome: 7.1 Apathy (AES only).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 7 Methylphenidate, outcome: 7.3 Adverse Events." data-id="CD012197-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 7 Methylphenidate, outcome: 7.3 Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Cholinesterase Inhibitors, outcome: 3.1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs)." data-id="CD012197-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Cholinesterase Inhibitors, outcome: 3.1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 1 Change in apathy from baseline as measured by the AES." data-id="CD012197-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 1 Change in apathy from baseline as measured by the AES. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 2 Change in apathy from baseline as measured by the NPI‐apathy subscore." data-id="CD012197-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 2 Change in apathy from baseline as measured by the NPI‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 3 Adverse Events." data-id="CD012197-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 3 Adverse Events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 4 Change in NPS from baseline as measured by the NPI." data-id="CD012197-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 4 Change in NPS from baseline as measured by the NPI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 5 Change in cognition from baseline as measured by the MMSE." data-id="CD012197-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 5 Change in cognition from baseline as measured by the MMSE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 6 Change in functional permance from baseline as measured by the ADL." data-id="CD012197-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 6 Change in functional permance from baseline as measured by the ADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 7 Change in functional performance from baseline as measured by the IADL." data-id="CD012197-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 7 Change in functional performance from baseline as measured by the IADL. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 8 Change in global disease severity from baseline as measured by the CGIC and the ADCS‐CGIC." data-id="CD012197-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 8 Change in global disease severity from baseline as measured by the CGIC and the ADCS‐CGIC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Methylphenidate, Outcome 9 Dropouts due to adverse events." data-id="CD012197-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Methylphenidate, Outcome 9 Dropouts due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil, Outcome 1 Change in apathy from baseline as measured by the FrSBe‐apathy subscale." data-id="CD012197-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Modafinil, Outcome 1 Change in apathy from baseline as measured by the FrSBe‐apathy subscale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Modafinil, Outcome 2 Change in functional performance from baseline as measured by the ADL‐Q." data-id="CD012197-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Modafinil, Outcome 2 Change in functional performance from baseline as measured by the ADL‐Q. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Cholinesterase inhibitors, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs)." data-id="CD012197-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Cholinesterase inhibitors, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Cholinesterase inhibitors, Outcome 2 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with disease severity)." data-id="CD012197-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Cholinesterase inhibitors, Outcome 2 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with disease severity). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Discontinuation of cholinesterase inhibitors, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore." data-id="CD012197-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Discontinuation of cholinesterase inhibitors, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Atypical antipsychotics, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore and the BPRS withdrawn depression factor score." data-id="CD012197-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Atypical antipsychotics, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore and the BPRS withdrawn depression factor score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Discontinuation of antipsychotics, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore." data-id="CD012197-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Discontinuation of antipsychotics, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Antidepressants, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore." data-id="CD012197-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Antidepressants, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Mibampator, Outcome 1 Change in apathy from baseline as measured by the FrSBe‐apathy T score." data-id="CD012197-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Mibampator, Outcome 1 Change in apathy from baseline as measured by the FrSBe‐apathy T score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Valproate, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore and GIP‐apathy subscore." data-id="CD012197-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Valproate, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore and GIP‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012197-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/urn:x-wiley:14651858:media:CD012197:CD012197-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_t/tCD012197-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Semagacestat, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore." data-id="CD012197-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Semagacestat, Outcome 1 Change in apathy from baseline as measured by the NPI‐apathy subscore. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/media/CDSR/CD012197/image_n/nCD012197-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012197-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared to placebo for apathy in Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Methylphenidate compared to placebo for apathy in Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Apathy in people with mild‐to‐moderate Alzheimer's disease<br/> <b>Setting:</b> Multicenter, USA and Canada<br/> <b>Intervention:</b> methylphenidate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Methylphenidate</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy (AES score)<br/> assessed with: AES<br/> Scale from: 0 to 42<br/> follow‐up: range 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy was ‐4.2 to 0.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.99 lower<br/> (9.55 lower to 0.43 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES: Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy (NPI‐apathy subscale score)<br/> assessed with: NPI‐apathy subscale<br/> Scale from: 0 to 12<br/> follow‐up: 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy ‐2.6 to ‐1.69</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.08 lower<br/> (3.85 lower to 3.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐ to 2‐point change suggested to be clinically significant in people with a clinically significant apathy (<a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> assessed with: Number of participants reporting ≥ 1 adverse event<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.28<br/> (0.67 to 2.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1, 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>684 per 1000<br/> (358 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NPS<br/> assessed with: NPI<br/> Scale from: 0 to 144<br/> follow‐up: 2 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in NPS was ‐2.08</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.16 higher<br/> (7.89 lower to 8.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point change suggested to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognition<br/> assessed with: MMSE<br/> Scale from: 0 to 30<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in cognition was ‐1.08 to ‐0.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.79 higher<br/> (0.53 higher to 3.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE: 2‐ to 4‐point change suggested to be clinically significant</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in functional performance assessed with: ADL scale<br/> Scale from: 0 to 6<br/> follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was 0.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.50 higher<br/> (0.39 lower to 1.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Change in functional performance assessed with: IADL scale<br/> Scale from: 0 to 8 for women, and 0 to 5 for men, to avoid potential for gender bias<br/> follow‐up: 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was ‐0.6</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 2.30 higher<br/> (0.74 higher to 3.86 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Change in global disease severity<br/> assessed with: ADCS‐CGIC or CGIC<br/> follow‐up: 2 weeks to 6 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.15 to 2.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>116 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (17 to 244) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dropouts<br/> assessed with: Number of participants who dropped out prior to study completion.<br/> follow‐up: 2 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.10<br/> (0.60 to 7.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>145<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>86 per 1000<br/> (25 to 303) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>AD:</b> Alzheimer's disease; <b>AEs:</b> Adverse Events; <b>MMSE:</b> Mini‐Mental Status Examination; <b>MD:</b> Mean Difference; <b>NPS:</b> Neuropsychiatric Symptom, <b>SMD:</b> Standardized Mean Difference, <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded one level due imprecision (wide 95% confidence interval).<br/> <sup>2</sup>Quality downgraded one level due to inconsistency (substantial heterogeneity was present).<br/> <sup>3</sup>Quality downgraded one level due to imprecision (only one study, with a relatively small sample size).<br/> <sup>4</sup>Quality downgraded two levels due to very serious imprecision (very wide 95% confidence interval). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate compared to placebo for apathy in Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012197-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Modafinil compared to placebo for apathy in Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Modafinil compared to placebo for apathy in Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Apathy in people with mild‐to‐moderate Alzheimer's disease<br/> <b>Setting:</b> Single site, USA<br/> <b>Intervention:</b> modafinil<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Modafinil</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in apathy<br/> assessed with: FrSBe‐apathy subscale (T‐score converted from raw score)<br/> Scale from: 14 to 70 (raw score)<br/> follow‐up: mean 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in apathy was ‐6.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.27 higher<br/> (3.51 lower to 4.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes on the FrSBe apathy score</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse Events ‐ reported, but not analyzed in this review</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NPS ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in cognition ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in functional performance<br/> assessed with: ADLQ<br/> Scale from: 0 to 84<br/> follow‐up: mean 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change from baseline in functional performance was 0</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.54 lower<br/> (1.40 lower to 0.32 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limited data on clinically meaningful changes</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in global disease severity ‐ not investigated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dropouts ‐ reported, but not analyzed in this review</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Quality downgraded two levels due to small sample size and imprecision (wide 95% confidence interval). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Modafinil compared to placebo for apathy in Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012197-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>STUDY DURATION</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N OF PARTICIPANTS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN AGE (YRS)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MEAN BL NPI‐APATHY (SD) score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COUNTRY</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NUMBER OF SITES</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TREATMENT GROUPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>METHYLPHENIDATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 weeks Cross‐over design: 2 treatment phases of 2 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA), and apathy (NPI‐apathy subscale ≥ 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.9 (7.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.9 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (10 mg twice a day)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants<br/> <b>Group 1:</b> 29<br/> <b>Group 2:</b> 31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA), and clinically significant apathy for at least 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 7 (2)<br/> <b>Group 2:</b> 7 (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (target: 20 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 participants<br/> <b>Group 1:</b> 30<br/> <b>Group 2:</b> 30 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia of the AD type (DSM‐IV‐TR), and presence of apathy (AES &gt; 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6 (7.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.8 (2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported<br/> <br/> (AES only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Methylphenidate (target: 20 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p><b>MODAFINIL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 11<br/> <b>Group 2:</b> 11 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA criteria) and clinically significant apathy (FrSBe Tscore ≥ 65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 75.3 (8.3)<br/> <b>Group 2:</b> 29.4 (7.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Modafinil (200 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>CHOLINESTERASE INHIBITORS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 103 </p> <p><b>Group 2:</b> 105 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD with cerebrovascular disease (but not vascular dementia) (NINCDS‐ADRDA criteria) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 85.4<br/> <b>Group 2:</b><br/> 85.9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 14.4 (5.4)<br/> <b>Group 2:</b> 14.4 (5.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil ‐ 5 mg/day for 28 days. 10 mg/day after 28 days based on tolerability.<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 144<br/> <b>Group 2:</b> 146 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD (DSM‐IV and NINCDS‐ADRDA criteria)<br/> <br/> moderate‐severe AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 11.7 (0.35)<br/> <b>Group 2:</b> 12.0 (0.34) ** </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 3.48 (0.29)<br/> <b>Group 2:</b><br/> 3.48<br/> (0.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada, Australia, France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil ‐ 5 mg/day for 28 days. 10 mg/day after 28 days based on tolerability.<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range: 3 ‐ 6 months (12 ‐ 24 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 1347<br/> <b>Group 2:</b> 686 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 2.34 (3.2)<br/> <b>Group 2:</b><br/> 2.32 (3.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, Canada, Great Britain, South Africa, Australia, and New Zealand</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Galantamine<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 273<br/> <b>Group 2:</b> 135 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Metrifonate (2 weeks – 2.0 mg/kg, followed by 0.65 mg/kg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 273<br/> <b>Group 2:</b> 135 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> mild‐moderate AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 73.5 (8.1)<br/> <b>Group 2:</b> 73.7 (7.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 18.8 (5)<br/> <b>Group 2:</b> 19.4 (4.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Metrifonate (2 weeks – 2.0 mg/kg, followed by 0.65 mg/kg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 177<br/> <b>Group 2:</b> 87 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)</p> <p>mild‐moderate AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 74.6 (8.3)<br/> <b>Group 2 :</b> 74.5 (7.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 18.7 (4.76)<br/> <b>Group 2:</b> 18.7 (4.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA (additional sites are not disclosed)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 50 mg, OD<br/> <b>Group 2:</b> placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>CHOLINESTERASE DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 21<br/> <b>Group 2:</b> 19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA criteria)<br/> <br/> moderate‐severe AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 8.1(5.2)<br/> <b>Group 2:</b> 10 (5.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 3.29 (4.0)<br/> <b>Group 2:</b><br/> 2.16 (4.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Donepezil,<br/> rivastigmine,<br/> galantamine (oral only)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ATYPICAL ANTIPSYCHOTICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 132<br/> <b>Group 2:</b> 125<br/> <b>Group 3:</b> 134 <br/> <b>Group 4:</b> 129<br/> <b>Group 5:</b> 129 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA criteria and DSM‐IV‐TR), and clinically significant psychotic symptoms </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.6 (10.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.7 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 3.2 (3.9)<br/> <b>Group 2:</b> 3.2 (3.7)<br/> <b>Group 3:</b> 3.4 (3.9)<br/> <b>Group 4:</b> 3.4 (3.7)<br/> <b>Group 5:</b> 3.0 (3.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Europe, Australia, Israel, Lebanon, and South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 7.5 mg OLZ<br/> <b>Group 2:</b> 5 mg OLZ<br/> <b>Group 3:</b> 2.5 mg OLZ <br/> <b>Group 4:</b> 1.0 mg OLZ<br/> <b>Group 5:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 36 weeks (12 weeks of treatment) data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 100<br/> <b>Group 2:</b> 94<br/> <b>Group 3:</b> 85<br/> <b>Group 4:</b> 142 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia of the AD type (DSM‐IV) or probable AD (NINCDS‐ADRDA) and daily delusions, hallucinations, agitation, or aggression over 4 weeks prior to study entry </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.9 (7.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 15 (5.4)<br/> <b>Group 2:</b> 14.9 (6.1)<br/> <b>Group 3:</b> 15.7 (6.1)<br/> <b>Group 4:</b> 14.7 (5.8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> OLZ<br/> <b>Group 2:</b> QUE<br/> <b>Group 3:</b> RIS<br/> <b>Group 4:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ANTIPSYCHOTIC DISCONTUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 28<br/> <b>Group 2:</b> 27 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dementia diagnosis according to ICD‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.4 (6.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.4 (1.5)<b>Group 2:</b> 1.9 (1.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norway</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Antipsychotics (haloperidol, risperidone, or olanzapine)<br/> <b>Group 2:</b><br/> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>ANTIDEPRESSANTS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks: Cross‐over design: 2 treatment phases of 4 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary degenerative dementia (DSM‐IV) and probable AD (NINCDS‐ADRDA), and significant behavioral problems (NPI ≥ 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.1 (4.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.27 (3.5)<br/> <b>Group 2:</b><br/> 1.45 (3.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Sertraline (100 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 94<br/> <b>Group 2:</b> 92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA), and significant behavioral problems (NPI ≥ 8), and clinically significant agitation on the NPI &gt; 3 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 78 (9)<br/> <b>Group 2:</b> 79 (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 17 (6.2)<br/> <b>Group 2:</b> 14.4 (6.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 6 (0.9)<br/> <b>Group 2:</b><br/> 6 (0.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Citalopram (30 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>MIBAMPATOR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 63<br/> <b>Group 2:</b> 69 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA) (DSM‐IV‐TR), and clinically significant agitation/aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 77.2 (8.2)<br/> <b>Group 2:</b> 77.7 (7.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 16.0 (6.1) <b>Group 2:</b> 18 (5.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multicenter, but number not disclosed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Mibampator (target dose: 3 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>VALPROATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks: Cross‐over design: 2 treatment phases of 6 weeks with a 2‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 14<br/> <b>Group 2:</b> 13 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Probable AD (NINCDS‐ADRDA), primary degenerative dementia (DSM‐IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.6 (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 2.4 (3.8)<br/> <b>Group 2:</b><br/> 3.0(4.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (mean dose: 1134.6 (400.1) mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks: Cross‐over design: 2 treatment phases of 3 weeks with a 1‐week washout between phases </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 42<br/> <b>Group 2:</b> 42 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Senile dementia (NINCDS‐ADRDA)(DSM‐IV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80.4 (6.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.4 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (2 x 240 mg)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months (+ 2‐month single‐blind placebo phase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 153<br/> <b>Group 2:</b> 160 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Possible or probable AD (NINCDS‐ADRDA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 74.9<br/> <b>Group 2:</b> 76.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 16.9 (3.0)<br/> <b>Group 2:</b> 16.9 (2.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> <br/> 1.1 (2.7)<br/> <b>Group 2:</b><br/> 1.2 (2.9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> Valproate (flexible‐dose) (mean modal dose: 250 mg daily)<br/> <b>Group 2:</b> Placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>SEMAGACESTAT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0016" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease2016;54(1):373‐81. [PUBMED: 27567808] ">Semgacestat trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 463<br/> <b>Group 2:</b> 472<br/> <b>Group 3:</b> 473 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild‐moderate AD (NINCDS‐ADRDA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 72.7 (7.9)<br/> <b>Group 2:</b> 73 (8.5)<br/> <b>Group 3:</b> 73.3 (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> 20.9 (3.5)<br/> <b>Group 2:</b> 20.8 (3.5)<br/> <b>Group 3:</b> 20.9 (3.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Group 1:</b> LY100<br/> <b>Group 2:</b> LY140<br/> <b>Group 3:</b> Placebo </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AD: Alzheimer's disease, BL: baseline, DSM: Diagnostic and Statistical Manual of Mental Disoders, FrSBe: Frontal Systems Behavior Scale, ICD: International Classification of Diseases, LY: LY450319 (Eli Lillyand Company study drug), NINCDS‐ADRDA: National Institute of Neurological and Communicative disorders and the Alzheimer's Disease and Related Disorders Association, NPI: Neuropsychiatric Inventory, OLZ: olanzapine, QUE: quetiapine, RIS: risperidone, SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study and participant characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012197-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome Measures and Assessments</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Apathy</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>AE reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NPS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cognition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global Change</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dropouts due to AEs reported</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>METHYLPHENIDATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0006" title="HerrmannN , RothenburgLS , BlackSE , RyanM , LiuBA , BustoUE , et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology2008;28(3):296‐301. [PUBMED: 18480686] ">Herrmann 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Informant<br/> <br/> NPI‐apathy subscale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CGI‐C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0014" title="RosenbergPB , LanctôtKL , DryeLT , HerrmannN , SchererRW , BachmanDL , et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2013;74(8):810‐6. [PUBMED: 24021498] ">Rosenberg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Informant<br/> <br/> NPI‐apathy subscale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐total (not reported)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐CGIC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0012" title="PadalaPR , PadalaKP , LensingSY , RamirezD , MongaV , BoppMM , et al. Methylphenidate for apathy in community‐dwelling older veterans with mild Alzheimer's disease: a double‐blind, randomized, placebo‐controlled trial. American Journal of Psychiatry2017;175:appiajp201717030316. [PUBMED: 28945120] ">Padala 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AES‐Clinician</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<br/> IADL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>MODAFINIL</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0003" title="FrakeyLL , SallowayS , BuelowM , MalloyP . A randomized, double‐blind, placebo‐controlled trial of modafinil for the treatment of apathy in individuals with mild‐to‐moderate Alzheimer's disease. Journal of Clinical Psychiatry2012;73(6):796‐801. [PUBMED: 22687392] ">Frakey 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FrSBe‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ADLQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>CHOLINESTERASE INHIBITORS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0019" title="TariotPN , CummingsJL , KatzIR , MintzerJ , PerdomoCA , SchwamEM , et al. A randomized, double‐blind, placebo‐controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Journal of the American Geriatrics Society2001;49(12):1590‐9. [PUBMED: 11843990] ">Tariot 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="6" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0011" title="FeldmanH , GauthierS , HeckerJ , VellasB , SubbiahP , WhalenE . A 24‐week, randomized, double‐blind study of donepezil in moderate to severe Alzheimer's disease. Neurology2001;57(4):613‐20. [PUBMED: 11524468] FeldmanH , GauthierS , HeckerJ , VellasB , XuY , IeniJR , et al. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial. International Journal of Geriatric Psychiatry2005;20(6):559‐69. [PUBMED: 15920715] GauthierS , FeldmanH , HeckerJ , VellasB , AmesD , SubbiahP , et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. International Psychogeriatrics2002;14(4):389‐404. [PUBMED: 12670060] ">MSAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0004" title="HerrmannN , RabheruK , WangJ , BinderC . Galantamine treatment of problematic behavior in Alzheimer disease: post‐hoc analysis of pooled data from three large trials. American Journal of Geriatric Psychiatry2005;13(6):527‐34. [PUBMED: 15956273] ">Herrmann 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0008" title="KauferD . Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders1998;9 Suppl 2:8‐14. [PUBMED: 9718229] ">Kaufer 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0010" title="MorrisJC , CyrusPA , OrazemJ , MasJ , BieberF , RuzickaBB , et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology1998;50(5):1222‐30. [PUBMED: 9595967] ">Morris 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0013" title="RaskindMA , CyrusPA , RuzickaBB , GulanskiBI . The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group. Journal of Clinical Psychiatry1999;60(5):318‐25. [PUBMED: 10362441] ">Raskind 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>CHOLINESTERASE DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0007" title="HerrmannN , O'ReganJ , RuthirakuhanM , KissA , EryavecG , WilliamsE , et al. A randomized placebo‐controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association2016;17(2):142‐7. [PUBMED: 26482056] ">Herrmann 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ATYPICAL ANTIPSYCHOTICS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0002" title="DeDeynPP , CarrascoMM , DeberdtW , JeandelC , HayDP , FeldmanPD , et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry2004;19(2):115‐26. [PUBMED: 14758577] ">De Deyn 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="2" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0018" title="SultzerDL , DavisSM , TariotPN , DagermanKS , LebowitzBD , LyketsosCG , et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE‐AD effectiveness trial. American Journal of Psychiatry2008;165(7):844‐54. [PUBMED: 18519523] ">Sultzer 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS‐withdrawn depression factor score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ANTIPSYCHOTIC DISCONTINUATION</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0015" title="RuthsS , StraandJ , NygaardHA , AarslandD . Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo‐controlled study‐‐the Bergen District Nursing Home study (BEDNURS). International Journal of Geriatric Psychiatry2008;23(9):889‐95. [PUBMED: 18306150] ">Ruths 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>ANTIDEPRESSANTS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0009" title="LanctôtKL , HerrmannN , VanReekumR , EryavecG , NaranjoCA . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. International Journal of Geriatric Psychiatry2002;17(6):531‐41. [PUBMED: 12112177] ">Lanctôt 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="2" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0001" title="LeonpacherAK , PetersME , DryeLT , MakinoKM , NewellJA , DevanandDP , et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD Study. American Journal of Psychiatry2016;173(5):473‐80. [PUBMED: 27032628] PorsteinssonAP , DryeLT , PollockBG , DevanandDP , FrangakisC , IsmailZ , et al. CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. The Journal of the American Medical Association2014;311(7):682‐91. ">CitAD trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>MIBAMPATOR</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0021" title="TrzepaczPT , CummingsJ , KonechnikT , ForresterTD , ChangC , DennehyEB , et al. Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics2013;25(5):707‐19. [PUBMED: 23257314] ">Trzepacz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FrSBe‐apathy T score</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>VALPROATE</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0005" title="HerrmannN , LanctôtKL , RothenburgLS , EryavecG . A placebo‐controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders2007;23(2):116‐9. [PUBMED: 17148938] ">Herrmann 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012197-bbs2-0017" title="SivalRC , HaffmansPM , JansenPA , DuursmaSA , EikelenboomP . Sodium valproate in the treatment of aggressive behavior in patients with dementia‐‐a randomized placebo controlled clinical trial. International Journal of Geriatric Psychiatry2002;17(6):579‐85. [PUBMED: 12112183] ">Sival 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GIP‐apathetic behavior subscore</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0020" title="TariotPN , SchneiderLS , CummingsJ , ThomasRG , RamanR , JakimovichLJ , et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry2011;68(8):853‐61. [PUBMED: 21810649] ">Tariot 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>SEMAGACESTAT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012197-bbs2-0016" title="DoodyRS , RamanR , FarlowM , IwatsuboT , VellasB , JoffeS , et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine2013;369(4):341‐50. [PUBMED: 23883379] RosenbergPB , LanctôtKL , HerrmannN , MintzerJE , PorsteinssonAP , SunX , et al. Changes in neuropsychiatric inventory associated with semagacestat treatment of Alzheimer's disease. Journal of Alzheimer's Disease2016;54(1):373‐81. [PUBMED: 27567808] ">Semgacestat trial</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI‐apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>These outcomes were not investigated for this drug comparison</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ADCS‐CGIC: Alzheimer's Diserase Cooperative Study ‐ Clinical Global Impression of Change, ADL: Activities of Daily Living scale, ADLQ: Lawton and Brody Fucntional Assessment, AES: Apathy Evaluation Scale, CGI‐C: Clinical Global Impression of Change, FrSBe: Frontal Systems Behavior Scale, GIP: The Behavior Observation Scale for Intramural Psychogeriatric Patients, IADL: Instrumental Activities of Daily Living Scale, MMSE: Mini‐Mental State Examination, NPI: Neuropsychiatric Inventory. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcome Measures and Assessments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/full#CD012197-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methylphenidate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the AES <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.99 [‐9.55, ‐0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.62 [‐4.80, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ≥ 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.90 [‐13.50, ‐6.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in apathy from baseline as measured by the NPI‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐3.85, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse Events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.67, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &lt; 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.44, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ≥ 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.73, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in NPS from baseline as measured by the NPI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐7.89, 8.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in cognition from baseline as measured by the MMSE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.06, 2.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 &lt; 12 weeks study duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐0.49, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 ≥ 12 weeks study duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.6 [1.43, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in functional permance from baseline as measured by the ADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐0.39, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in functional performance from baseline as measured by the IADL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.3 [0.74, 3.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in global disease severity from baseline as measured by the CGIC and the ADCS‐CGIC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.16, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Dropouts due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.64, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Methylphenidate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the FrSBe‐apathy subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐3.51, 4.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in functional performance from baseline as measured by the ADL‐Q <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.40, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Modafinil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cholinesterase inhibitors</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with licensed versus unlicensed ChEIs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.80, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Licensed ChEIs (and ≤ 24 weeks study duration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.85, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unlicensed ChEIs ( and &gt; 24 weeks study duration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐0.98, ‐0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Change in apathy from baseline as measured by the NPI‐apathy subscore (subgroup analysis with disease severity) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.80, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Moderate AD (MMSE ≥ 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.79, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Severe AD (MMSE &lt; 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.82, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Cholinesterase inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Discontinuation of cholinesterase inhibitors</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [‐0.88, 3.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Discontinuation of cholinesterase inhibitors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Atypical antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore and the BPRS withdrawn depression factor score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 0.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Atypical antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Discontinuation of antipsychotics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.51, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Discontinuation of antipsychotics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Antidepressants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.24 [‐1.44, ‐1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Antidepressants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Mibampator</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the FrSBe‐apathy T score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.2 [‐1.94, ‐0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Mibampator</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Valproate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore and GIP‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.23, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Valproate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012197-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Semagacestat</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in apathy from baseline as measured by the NPI‐apathy subscore <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.15, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Semagacestat</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012197.pub2/references#CD012197-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012197.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012197-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012197-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012197-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012197-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012197-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012197-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012197-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012197\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012197\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012197\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012197\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012197\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012197.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012197.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012197.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012197.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012197.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713921470"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012197.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713921474"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012197.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d62113987937a',t:'MTc0MDcxMzkyMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 